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Abstract 
Abstract 
The potential application of inkjet printing technology to produce precisely dosage 
care is demonstrated in this thesis. Inkjet printing technology as it offers the 
opportunity to deliver quantities with high accuracy can produce medicines tailored 
for each patient. 
The viability of this method was first demonstrated by using Felodipine as an active 
pharmaceutical ingredient polyvinyl pirrolidone (PVP) as an excipient. Felodipine is 
an antihypertensive drug which is poorly soluble in water and PVP is a highly soluble 
polymer commonly used to improve drugs' bioavailability. These were dissolved at 
various ratios in a mixture of ethanol and DMSO (95/5). Using a piezoelectric driven 
dispenser, picolitre size droplets of the solutions were dispensed onto suitable 
hydrophobic substrates. The dried products were characterized using AFM, localized 
nano-thermal analysis and high resolution vibrational spectroscopy (ATR-IR and 
Raman). Results indicate intimate mixing of the micro-dot API and excipient 
mixtures. Specifically, ATR-IR confirmed the interaction of felodipine and PVP by 
means of hydrogen bonding. Nanothermal analysis indicates a single glass transition 
point which is lowered as the API concentration increases. Finally, confocal Raman 
microscopy mapping on single droplets allows the visualization of the homogeneous 
distribution of the drug. 
Also, capozide has been used as a model therapeutic system which could be 
produced rapidly as a viable formulation using the inkjet printing technology. 
Capozide consists of captopril, an angiotensin converting enzyme (ACE) inhibitor and 
hydrochlorothiazide, a thiazide diuretic drug, in varying ratios. These active 
pharmaceutical ingredients (APls) and poly(lactic-co-glycolic acid) (PLGA) were 
dissolved in appropriate solvents and using a piezoelectric driven dispenser and 
pipetting, picolitre and microlitre size droplets respectively were deposited onto 
hydrophobic coated glass slides. Captopril and PLGA were dissolved in chloroform, 
ethanol and DMSO (75/18/7). Hydrochlorothiazide (HCT) and PLGA were dissolved in 
acetone and DMSO (93/7). The dried products where characterised using AFM and 
II 
Abstract 
high resolution Raman microscopy. The results showed that both capropril and HCT 
are phase separated with the PLGA. Also, the dissolution profiles of the final 
products were measured using HPLC where it has been shown that PLGA can control 
the release of the drug from the formulation. These results are a promising first step 
to produce pharmaceutical by means of inkjet printing. 
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1. Introduction 
1.1 Current trends in oral dosage drug formulation production 
Nowadays the most popular drug delivery systems are tablets and intravenous 
solutions. The advantages that they can offer are the greater stability, pain 
avoidance, versatility, patient compliance accurate dosage and easy production [1-2]. 
Tablets are compressed powders. The main aim of these compressed powders is to 
be easily dissolved in the gastrointestinal tract and aid in the complete absorption of 
API. The tablet manufacture process can be classified as granulation (wet and dry) 
and direct compression. Direct compression is the term used to define the process 
where powder blends of the drug substance and excipients are compressed on a 
tablet machine. There is no mechanical treatment of the powder apart from a mixing 
process. Granulation is a generic term for particle enlargement, whereby powders 
are formed into permanent aggregates. In granulation, the particles are 
agglomerated to improve the flow, density and compressibility of particulate 
material by size enlargement. The agglomeration can be achieved by using a dry 
binder (dry granulation) or a binder solution (wet granulation) which stick the 
individual particles together. 
More speCifically in dry granulation, the powder blends are compacted through roller 
or slugging compactions. Slugging involves the manufacture of a large compressed 
tablet, whereas roller compaction pushes powder blends through two counter-
rotating rolls, producing a sheet of agglomerated material [3-4]. The main advantage 
of dry granulation is that the powders are not exposed to moisture and dry process. 
However, the applied mechanical stresses during processing may lead to phase 
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transformation via the solid-state or melt mechanisms [5]. Also, the tablets produced 
when materials possess a low bulk density may be too thin after compression. 
Finally, dry granulation is not suited for poorly flowing drug compounds [2]. 
Wet granulation provides better control of drug content uniformity at low drug 
concentrations, as well as control of product bulk density and ultimately 
compactibility (brittle fracture), even for high drug contents. Wet granulation 
involves two types of processing; fluid bed granulators or high-shear mixers. Wet 
granulation typically involves wet massing a blend of API and excipients in a wet 
granulator followed by subsequent sieving and finally drying [3-4]. However, during 
wet granulation process different crystalline polymorphs of the API can be formed 
[6-7]. Other limitations of wet granulation are the expensive equipment and the 
solvent recovery when it is not used as water as a solvent. 
In direct compression the powder blends of APls and excipients are compressed on a 
tablet machine. The advantages over the granulation process are the lower cost as it 
is much simpler not requiring many operations granulations. However, the inherent 
physical properties of the individual filler materials are highly critical, and minor 
variations can alter flow and compression characteristics, so as to make them 
unsuitable for direct compression [3-4]. Armstrong described the requirements for 
direct compression fillers which must have good flow properties, possess good 
compaction properties, have appropriate particle size to avoid segregation and have 
high bulk density [8J. Various excipients are available now that allow tablet 
production without granulation process intervenes such as microcrystalline cellulose, 
starch 1500 and lactose [2J. 
From all the above it is clear that the first choice as a tablet manufacture method is 
the direct compression due to its low cost. However, this method is not always 
applicable as it requires specific properties from the compounds and also it cannot 
be used for drug loading more than 30% [4J. Hence, the manufacture part of a 
formulation requires a considerable amount of cost and time. Consequently, a 
simpler generic method to produce solid drug dosages would revolutionize the 
pharmaceutical industry. Inkjet printing is a well established method for transferring 
quantities with high accuracy and perfectly localised [9-11]. In this case, the active 
compound can be dissolved with excipients depending on the properties of the final 
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formulation product. By implementing, inkjet printing in drug formulation many of 
the excipients required in manufacture such as lubricants, binders, fillers etc. will not 
be necessary. Also, properties of the compounds that affect the tablet's properties 
such as compactability, bulk density, particle size, melting points cannot be 
considered as the most important properties will be taken into account are the 
solubility of the compounds and the viscosity of the solution that will occur. A more 
thorough analysis of inkjet printing is represented in chapter 1.5. 
1.2 Stability in drug formulations 
One of the major concerns in pharmaceutical industry is the long term stability of the 
formulation product. There have been drugs with the best therapeutic properties but 
failed to come to the market due to lack of physical and chemical stability. For 
instance ritonavir was marketed by Abbott in 1996, however two years later lots of 
capsules failed the dissolution experiments due to the formation of another 
polymorph of the drug [12]. The main factors that affect the stability of product are 
heat, humidity, oxidation and light. 
Humidity can have a significant effect on solid drug substances or drug products. 
First of all, humidity can alter the adhesion properties of API with excipient. Price et 
01. found that the adhesion interactions between lactose and drug probes of 
salbutamol sulphate and budesonide were shown to be significantly increased with 
each incremental rise in humidity. This could result to a reduction of the disperSion 
and deaggregation properties of a DPI formulation, influencing the aerolisation 
efficiency and therapeutic efficacy of the irrespirable drugs to the respiratory tract 
[13]. Also, uptake of moisture can have a plasticization effect to any of the 
compounds in the formulation reducing the glass transition temperature [14]. For 
instance, the glass transition temperature of sucrose can range between 60 - 75°C 
depending on the water uptake from each sample [15]. The high mobility that 
molecules have on glass transition temperature can lead to crystallization of the 
product which in turn can affect dramatically the therapeutic properties of the drug. 
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Hydrolysis is a common phenomenon that happens to pharmaceuticals. This happens 
when the compound comes into contact with water. Hydrolysis is often the main 
degradation pathway for drug substances having ester and amide functional groups 
within their structure [16]. Example can be hydrochlorothiazide, a drug substance 
with excellent solid-state stability, can undergo hydrolysis to form formaldehyde and 
4-amino-6-chloro-1,3-benzenedisulphonamide. Desai et 01. have shown that the 
inclusion of povidone K-30 NF (PVP) as binder and poloxamer 188 NF (Pluronic F68) 
as a wetting agent significantly increases drug hydrolysis during storage [17]. 
Oxidation is a well-known degradation pathway for pharmaceuticals. Compounds can 
be oxidised by the atmospheric oxygen. Hydrocortisone, meth-otrexate, adinazolam, 
hydroxyl group directly bonded to an aromatic ring (eg, phenol derivatives such as 
catecholamines and morphine), conjugated dienes (eg, vitamin A and unsaturated 
free fatty acids), heterocyclic aromatic rings are some of the compounds that can be 
subjected to oxidative degradation [16]. 
light can also affect the stability of the formulation leading to changes in the 
physico-chemical properties of the product. light-sensitive drugs can be affected 
either by sunlight (especially ultraviolet irradiation) or artificial light sources (e.g. 
fluorescent light). This may not only lead to photodegradation of the active 
pharmaceutical ingredient but also to a change in the physico-chemical properties of 
the product, e.g. the product becomes discolored or cloudy in appearance, a loss in 
viscosity or a change in dissolution rate is observed or a precipitate is formed [18]. 
From all the aforementioned it is clear that stability's investigation can be a big part 
of the research to bring a medicine to the market. Consequently, the ability to 
produce optimized formulations immediately prior to use can be the key to address 
the huge amount of research to achieve the long term formulation stability. Inkjet 
printing has the potential to produce precise amount of medicine which are 
preordained for instant consumption. A controller connected with the patient's 
personal doctor, can control the delivery of one or more drugs and/or change the 
drug regimens in response to a changing in medical conditions of the patient. The 
formulation can be prepared directly and consumed instantly. 
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1.3 Poorly soluble drugs; challenges and prospects 
Solubility is one of the most important factors that influence bioavailability of the 
drugs. The drug is first released from the formulation and through the 
gastrointestinal wall, it is transferred to the circulation system [19]. 
Various approaches have been used to improve solubility and enhance the 
dissolution rate of poorly soluble drugs involving both physical and chemical 
modification [20]. The physical modification aims to increase the surface area and 
wettabiJity of the API. This approach focuses on particle size reduction [21] and the 
generation of amorphous state [22]. The particle size reduction by milling aims at 
increasing the surface area of the particles and thus increasing the solubility. This 
technique has been applied to a variety of poorly soluble drugs [23-26]. Other 
approaches to increase the solubility involves the solubilization with surfactants and 
complexation with cyclodextrins [27]. 
One of the most promising strategies to increase the solubility of the drug is the 
dispersion of it into a hydrophilic inert polymer matrix. The two major methods to 
produce solid dispersion products are the melting and the solvent evaporation 
method. The melting process was first applied by Sekiguchi and Obi when they found 
that the administration of a fused mixture of the poorly water-soluble drug 
sulphathiazole and the water-soluble carrier urea produced an enhanced absorption 
of the drug in rabbits [28]. In the melting method the active compounds are 
suspended in a previously melted carrier with subsequently cooling and solidify the 
mixture. The main disadvantage of this method is the degradation of the drug or the 
carrier can be caused by the heat [29]. 
The solvent evaporation method consists of the solubiJisation of the drug and a 
polymer into a volatile solvent that is later evaporated. The final product will be an 
amorphous carrier in which the drug is molecularly distributed. This type of solid 
solution will be homogenous. Also, the product can be an amorphous carrier where 
the drug is dispersed in the form of amorphous clusters. This type is not homogenous 
on a molecular level and consists of two phases [20]. The most common polymers 
have been used are Polyvinyl Pyrrolidone (PVP) [3D], Polyethylene Glycols (PEGs) [3D-
31], Polyvinyl Alcohol (PVA) [32] and cellulose derivatives such as HydroxyPropyl 
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Methylcel/ulose (HPMC) [30] and HydroxyPropylCeliulose (HPC) [33]. Common 
characteristics of these polymers are that they are water soluble, soluble in most 
common organic solvents and they can interact with API by forming bonds such as 
hydrogen bonding. 
Despite the growing interest of solid dispersion, its commercial value is still limited. 
The main reason for this is the poor stability. The physical instability of the product 
can come from the recrystallization of the API. However, different polymers, which 
are used to solid disperSion, have been shown that inhibit the crystallization of the 
drug [34). In particular PVP has been found to have significance inhibitory effects of 
the drugs crystallization [35-38). The mechanism of inhibition of PVP involves the 
antiplasticising effect of PVP as well as specific interaction with the API [37]. 
However due to their chemistry and polarity, these polymers are highly hygroscopic 
which by absorbing water can promote the crystallization [22] which in turn can 
causes phase separation. For instance, Rumodor et 01 by investigating the phase 
behaviour of amorphous solid dispersions found that although the drug and the 
polymer were completely miscible immediately after the manufacture, they 
exhibited phase separation during storage and in elevated humidity [39]. 
Additionally, changes in the dissolution rate during storage have been observed [40-
41]. 
Other issues which limits the commercial application of solid dispersion are referred 
by Serajuddin [29] and these can involve any residual solvent that can not be 
removed from the solid dispersions, the scale up of the manufacturing process, and 
the dosage form development. The manufacture issues come from that the texture 
of the product is soft and tacky and therefore difficult to pulverize. Other issues are 
the poor flow, mixing properties of powders and poor compressibility. 
Inkjet printing can be the key technology to overcome the aforementioned issues 
and the solid dispersion technology becomes a commercial reality. In inkjet printing, 
as in the solvent evaporation method, both the API and the excipients will be 
dissolved in an appropriate solvent. The solvent will be evaporated leaving the 
product onto an appropriate substrate. As it was mentioned in the previous section, 
inkjet printing is preordained to produce drug for instant consumption and hence the 
long term stability is not necessary. An application of this is represented in chapter 3 
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where the poorly soluble felodipine dissolves with PVP in ethanol and ejected using 
an inkjet printer. However, it is worth mentioning that the compounds must remain 
stable when they are dissolved in the solvents before they are sprayed. Also, the 
phenomenon of polymorphism must be taken into account as depending on the 
solvent used different crystalline forms of the API can be grown [42] 
1.4 Technologies in Controlled drug delivery systems 
Conventional dosage forms are not able to control the rate of drug delivery or the 
target area and provide an immediate of drug release. As a result, drug 
concentration in the blood and tissue fluctuates widely. In controlled release drug 
dosage forms (CROOS), the drug is at maintained the necessary therapeutic levels 
with narrow fluctuations reducing the frequency of drug administration and 
improving the treatment efficiency (Figure 1.1). 
Generally, natural and synthetic polymers are used as the structural backbone for 
controlled release drug delivery system. Among all, the CRODS the monolithic matrix 
is the simplest and least expensive used. The polymer is homogenously distributed 
with the drug by blending the drug with the polymer and then molding, extruding, or 
casting them together. The dissolution profile of the drug from the polymer matrix 
can follow various mathematical models [43-44]. For instance pharmaceutical dosage 
forms which contains water soluble drugs in porous matrices for which the Fick's low 
governs the release of the dru& follow the first order mathematical model [44]. 
The disadvantage of this diffusion controlled system is the decreasing amount of the 
drug with time. Therefore, various approaches employing release mechanisms other 
than diffusion control have been developed to achieve constant release rates in 
polymer matrix devices, for example, swelling controlled delivery systems based on 
hydrogels [45-47], erosion polymers [48] and osmotic pressure pumps. 
Hydrogels are three-dimensional crosslinked polymeric structures that are able to 
swell in an aqueous environment. During the dissolution of the hydrogel two 
phenomena take place; swelling and true dissolution of the polymer. In the early 
stage of drug delivery, matrix thickness increases due to polymer swelling. The 
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successive polymeric chain disentanglement (true polymer dissolution), and the 
dissolution of the drug or fillers used, counteracts this increase in thickness, 
producing a diminution of the volume of the matrix. Finally, the matrix disappears 
when all the polymer is swollen [45]. Examples of polymers are used as hydrogels are 
ethylene glycol dimethacrylate, Methoxyethoxyethyl methacrylate, Methacrylic acid 
etc. All the common polymers are mentioned in the excellent review of Hamidi et 01. 
[46]. 
In terms of polymer erosion, there are two mechanisms can be identified; surface 
and bulk erosion. Bulk erosion occurs when water molecules are able to permeate 
into the bulk of the polymer matrix at a quicker rate than erosion. The surface 
erosion occurs when the polymer degradation is much faster than the water 
intrusion (Figure 1.2). Polyanhydrides are examples of bulk erosion materials 
whereas poly(lactide) and poly(lactide-co-glycolide) are surface erosion materials 
[48-49]. 
Osmotic systems utilize the principle of osmotic pressure to deliver drugs. When the 
dosage form comes into contact with water, imbibes water at a rate dependent on 
the fluid permeability of the membrane and osmotic pressure of the core 
formulation. This osmotic imbibition of the water causes a saturated drug inside the 
core which is dispensed at a controlled rate (Figure 1.3) [50]. Various types of 
osmotic pumps are in the market nowadays [51]. 
A final approach can be applied to control the drug release is the utilization of 
polymers as film coatings. Different types of polymers can be used as coatings. For 
instance cellulose derivatives, poly(vinyl acetates) and polymethacrylates. Also, 
blends of enteric and gastro-intestinal-tract (GIT)-insoluble polymers are particularly 
interesting for the coating of solid dosage forms, being able to provide large ranges 
of drug release profiles at low as well as at high pH [52]. Hence, as ethyl cellulose is 
poorly permeable from the drugs, it is usually added with PEG [53], PVP [54], and 
hydrophilic cellulose ethers [55-56). These hydrophilic additives are dissolved and 
leach out from the polymeric membranes resulting in a more permeable films and 
increased drug release rates. 
Apart from the polymer coating technology systems, matrix systems made of 
swellable and non swellable polymers and osmotically controlled devices discussed 
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above, more sophisticated CRDDS are still being developed. These systems are based 
on microparticulate systems which involves polymeric biodegradable nanoparticles 
which aim at the uptake the drug particles intact. This approach is promising in the 
case of delivering peptides and other macromolecules which normally cannot be 
administered orally [57-58]. 
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Figure 1.1: Drug concentration at the site of therapeutic action after delivery as a conventional injection 
(thin line) and as a temporal controlled release system (bold line) [49] . 
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Figure 1.2: schematic illustration of surface and bulk erosion [48] . 
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1.5 Inkjet printing 
1.5.1 Introduction 
1. Introduction 
Inkjet printing can be defined as the deposition of functional materials in the form of 
a liquid onto a specific substrate. The most common application is the transfer of 
electronic data to paper. However, nowadays more and more applications demands 
of the accurate transferring materials with specific electrical, biological or optical 
properties on substrates. Inkjet printing is one of the most promising technologies on 
that matter [59-60) 
The main advantage of this met hod is that it offers high accuracy and throughput of 
fluids. Nano or even pico quantities of materials can be transferred and perfectly 
localized. Also, the high uniformity and small size of the droplet generating renders 
this technique capable of producing precise micro features. Exploiting this capability, 
microelectromechanical systems (MEMS) has been improved by localized features 
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which were not possible by photolithography and also, transistor made by injected 
semiconductive organic thin film have been fabricated [61-62]. 
1.5.2 Inkjet printing technology 
Inkjet printing is fundamentally divided into continuous and drop on demand mode. 
In continuous mode the liquid is pressurised to form a jet through a nozzle. By 
imposing a periodic perturbation, uniform droplets are formed (Figure 1.5). 
Continuous mode is used for high speed graphical applications such as textile 
printing and labelling. In drop on demand mode the liquid is held and pressurised 
creating a droplet only when needed (Figure 1.6) [63]. 
Depending on the technology implemented, inkjet printing is categorised into 
thermal, piezoelectric, electrostatic and acoustic inkjet. An excellent paper was 
published by Hue which describes each technology [64]. Thermal and piezoelectric 
are the most widespread technologies, whereas the latter ones are still in the 
development stages. In thermal inkjet, the ink is heated creating a rapid expanded 
vapour bubble which ejects from the nozzle. Depending on its configuration, a 
thermal ink-jet can be a roof-shooter (Figure 1.7a) with an orifice located on top of 
the heater, or a side-shooter (Figure 1.7b) with an orifice on a side located nearby 
the heater. The roof-shooter design is used in the printheads from Hewlett-Packard, 
Lexmark, and Olivetti. The side-shooter design is implemented in the Canon and 
Xerox printheads [64J. 
Piezoelectric dispensers rely on the deformation of a piezoelectric material. When 
voltage applied the piezo material changed its shape to a preordained direction, 
causing a sudden volume change creating pressure waves which results In a drop 
being ejected from the orifice. Depending on the deformation of the piezoelectric 
material, the technology can be classified into four main categories; squeeze mode 
where radially polarised tubes are used, bend and push mode design where the 
electric field is generated between the electrodes parallel to the polarization of the 
piezo electric material and finally shear mode where the electric field is 
perpendicular to the polarization of the piezoceramic (Figure 1.8) [9, 65-66]. 
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In the electrostatic dispensers, an electric voltage is applied in the form of a signal 
between two electrodes. Due to the applied voltage, an intense electric field is 
generated between the two electrodes which induce the liquid meniscus at the 
interface. When this electrostatic force is greater than the surface tension at the 
liquid meniscus, the liquid breaks up and droplets are ejected (Figure 1.9) [67]. 
Acoustic droplet ejection (ADE) uses a pulse of ultrasound to move low volumes of 
fluids (typically nanoliters or picoliters) without any physical contact. This technology 
focuses acoustic energy into a fluid sample in order to eject picolitter size of 
droplets. The acoustic droplet ejection process (Figure 1.10) transfers nanoliter or 
picoliter droplets from a conventional flat-bottom microplate (A) using acoustic 
energy (8) from the transducer (C). The energy is focused on the surface of the 
liquid in the lower well, causing a droplet of precise volume to be ejected without 
any physical contact between the transducer and the liquid being dispensed [68]. 
The most important properties of liquid in dispensers that implement a piezoelectric 
response are viscosity, surface tension and density. These fluid properties influence 
the drop formation mechanism and subsequent drop size at a given voltage. Also, 
these properties can provide information about the impact of the droplet into the 
substrate. Schiaffino and Sonin classified the drop impact into four different regimes 
We = pDV
2 o. = 11/ 
according to Weber ( tT) and Ohnesorge ( JDpa ) numbers, 
where p is the density of the liquid, 0 is the diameter of the drop before impact, U is 
the impact velOCity, (J is surface tension, and n is the viscosity of the liquid. In regime 
I, where We »1 and Oh «1, kinetic energy dominant motion prevails, and fluid 
behaves almost like an in viscid fluid; in regime II, where We » 1 and Oh » 1, 
capillarity drives the motion of in viscid fluids; in regime III, where We « 1 and Oh 
»1, capillary effect is dominant, and the viscosity of the fluid is important; finally, in 
regime IV, where We »1 and Oh » 1, kinetic energy dominates the capillarity, and 
the viscous force is also important [69]. Jang et 01 investigated the printability of the 
fluids by applying the inverse (Z) of the Ohnesorge number (Oh) which relates to the 
viscosity, surface tension, and density of the fluid. They have experimentally defined 
the printable range as 4 < Z < 14 by considering characteristics such as single droplet 
formability, positional accuracy, and maximum allowable jetting frequency. This 
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range of Z corresponds to low viscosity fluid [70] . Yang et 01 showed that a smaller 
value of surface tension represents a weaker cohesive which leads to a slender liquid 
ligament with a relatively longer break up length. The shapes of the liquid and tail 
droplet tend to be round for the cases of high surface tension . It also takes more 
time for contraction of a spherical droplet for the liquid with lower surface tension 
[71]. 
Finally, the volume of the droplet is directly dependent on the voltage and the 
duration of the signal that is applied . Hence, the droplet velocity and volume are 
found to show a linear relation with driving voltage, but show a more complicated 
and periodic behaviour with changing frequency and pulse width . Derby et 01 showed 
that droplet velocity exhibits a maximum as a function of pulse width, which remains 
unchanged when driving voltage amplitude increased [72]. 
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Figure 1.5: Schematic diagram of continuous inkjet printing system [9]. 
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A 
Figure 1.10: schematic diagram of acoustic drop on demand dispenser [68] . 
1.5.3 Inkjet Printing in life sciences 
In life sciences inkjet printing has been proved a key technology. Compound 
synthesis, genomics, drug screening, drug delivery and biomaterials are some of the 
areas where this technique is or can be applied offering unique capabilities. All of 
these applications are driven by the desire to miniaturize process in order to achieve 
higher cost efficiencies and better detail. 
In high throughput screening, higher density well plates have started being used to 
reduce reagent costs and to obtain more information from each plate run through 
the screening process. The first step in HTS is to transfer a small quantity of 
compound from the master plate to the assay plate. By applying microdispensing 
technology the compound can be transferred in well-plates in various concentrations 
even in nanolitters, avoiding the intermediate dilution step. After the assay is 
prepared, it is conducted by a series of reagent additions and incubations followed 
by a read-out of the results [10-11] . 
In genomics, the basic application involves the dispensing DNA or synthetic 
oligonucleotides onto substrates and probing for complementary base-pair binding. 
Yamamoto et al managed to fabricate DNA microarrays by means of a bubble jet ink 
device to eject oligonucleotides to a glass surface. In that case, the dispenser, 
ejecting pico litter solution, was able to achieve highly densed spots per cm 2• These 
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were screened with a f1uorescently labeled synthetic 18-mer oligonucleotide derived 
from the p53 gene, or segments of the p53 gene that had been PCR amplified from 
genomic DNA of two cell lines of human oral squamous cell carcinoma (SCC). This 
allowed us to discriminate between matched hybrids and 1 bp-mismatched hybrids 
[73]. 
Apart from the well-established applications of inkjet printing in genomics and HTS, 
inkjet printing is a novel technique with respect to the biomaterial fabrication. An 
interesting study comes from the Barralet et 01 group. In this study, implants based 
on calcium 3D phosphate structures involving hydroxyapatite and brushite ceramics 
were printed by spraying calcium phosphates powders [74]. Also, for medical devices 
such as drug-containing stents, ink-jet technology due to the controllable and 
reproducible nature of the droplets in the jet stream and the ability to direct the 
stream to exact locations on the device surfaces can offer a boost to the cost of the 
procedure. Tarcha et 01 programmed target deliveries of 100 Il8 of drug, a typical 
dose for a small stent, into cuvettes which gave a standard deviation (SO) of dose of 
0.6 1lB. Jetting on coated, uncut stent tubes exhibited 100% capture efficiency with a 
1.8 Il8 SO for a 137 Il8 dose. In preliminary studies, continuous jetting on stents can 
yield efficiencies up to 91% and coefficients of variation as low as 2%. These results 
indicate that ink-jet technology may provide significant improvement in drug loading 
effiCiency over conventional coating methods [75]. 
1.5.4 Inkjet printing in drug formulation 
Inkjet printing as a drug formulation method is a novel technique. To date, the 
literature concerning this issue is limited. Thermal inkjet technology has been utilized 
by the Hewlett Packard's laboratories to prepare solid dosage forms of drugs. This 
group promoted this method as an alternative technique for low water soluble active 
pharmaceutical ingredients (APls). Therefore, they chose prednisolone as a test 
molecule due to its low solubility in water [76]. 
Inkjet printing has been applied as an alternative technique to fabricate therapeutic 
agents with the appropriate size and shape. By applying the current inkjet 
technology, amphiphiles, dissolved in ethanol solution, were sprayed into water 
forming small unilamellar vesicles with diameter 50-200 nm which can be used as 
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drugs' carriers. The group demonstrated this method as one that allows excellent 
control and reproducibility of particle size and shape, together with efficient 
encapsulation [77]. Furthermore, Radulescu et 01 by using inkjet technology and 
simple emulsion-solvent evaporation technique prepared PLGA microcapsules 
loaded with paclitaxel. Paclitaxel and PLGA were dissolved in OCM and sprayed in 
PVA solution. After the solvent removal, the product was PLGA spheres having 
encapsulated paclitaxel with 66.7% efficiency [78]. A similar work has been 
accomplished by Xie et ai, where PLGA biodegradable nanoparticles produced to 
encapsulate protein based drug using a co-axial electrospray technique [79]. 
Moreover, Chan et 01 using inkjet printing technology, they deposited mixtures of 
ibuprofen and PEG 6000. Subsequently, by using ATR properly modified, they 
characterized the samples by investigating the distribution of ibuprofen in the 
mixture [80]. Finally, Kastra el at by using three dimensional printing technique 
(30P), they prepared erosion mechanism delayed-release tablets with varying 
polymer content [81]. In 30P technique, layers are created by adding layers of 
powders at the top of a piston using inkjet printing. The powder layers are selectively 
joined each other where the where the part is to be formed by 'ink-jet' printing of a 
binder material [82]. 
The benefits of inkjet printing in drug formulation can be various. As it was 
mentioned earlier, a drug formulation consists of the API and several other polymers 
which are used during the manufacture process. The implementation of inkjet 
printing in drug formulation will render these polymers unnecessary and a big part of 
the manufacture process avoidable. 
Also, this technique has the potential to produce medicines for instant consumption. 
APls along with the necessary excipients and the appropriate solvents can be sold 
and ejected through an inkjet printing device. At this point, it is worth mentioning 
that the consequently, long term stability issues will be avoided. 
Another potential application of this technique deals with the recent advances in 
pharmacology. In the future, the therapy will be determined by the specific genotype 
for each patient. Hence, it is possible that each patient will be provided with his own 
cartridges of drug, to print each own drug with the right dosage. 
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1.6 Aims and objectives of thesis 
So far the reader has been introduced to various issues that need to be overcome 
during the tablet manufacture. These can be related to the cost of manufacture due 
to the use of various excipients to give to the processed compounds the appropriate 
compressibility, stability and release profile and the long term stability studies must 
take place. 
The aim of this thesis is to introduce inkjet printing as a novel drug formulations 
technique which could produce medicine preordained for instant consumption and 
hence avoiding any manufacture and stability issue. Also, since the inkjet printing 
technology offers high fluid delivery accuracy, a successful implementation of this 
technology can offer the ability to produced precise amounts of medicine, tailored to 
individual patients. 
The feasibility and efficiency of inkjet printing to produce proper drug formulation 
product is investigated in this thesis by spraying various APls with excipients and 
characterising them with micro- and nano- analytical methods. 
Hence, in the third chapter, the nano-scale production of drug formulations by 
means of inkjet printing technology is described. The formulations consisted by 
felodipine and hydrochlorothiazide with PVP and Captopril with Hydrochorothiazide 
with PlGA in various ratios. 
In Chapter 4, the release of the felodipine from the felodipine/PVP drug formulation 
produced by inkjet printing in microscale is investigated be means of confocal Raman 
microscopy. 
Chapter 5 attempts to increase the production scale of felodipine/PVP drug 
formulation so that the felodipine to be in the therapeutic amount by producing a 
microarray of the formulation. 
Fina"y, chapter 6 investigates the feasibility of inkjet printing to produce capozide as 
a model therapy. As Capozide tablet consists of captopril and HCT, inkjet printing can 
produce the tablet by preparing individual formulations of each API onto a single 
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substrate to consists a therapy. Also, the feasibility of PLGA to control the drug 
release from the formulation has been investigated. 
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2. Instrumentation 
2.1 Pico-litre dispenser 
The dispenser used in this thesis is a piezo-driven dispenser (GeSim, Germany) 
(Figure 2.1a) mounted on a Kruss Drop shape Analysis system (DSA 100, Kruss, 
Germany) (Figure 2.1d). The microdispenser was created from microstructured 
silicon and glass chips, tightly connected. The piezoelectric material is glued outside 
of the thin silicon wafer (Figure 2.1b). By applying a voltage, the piezoelectric 
material goes out of shape in a specific direction. This distortion is transferred to the 
solution causing the formation of a small droplet (Figure 2.1c). 
The overall volume of the droplets is determined by the dispenser type (mainly by 
the size of the orifice). However, the droplet volume can be tuned by adjusting piezo 
parameters (amplitude, pulse width, excitation frequency); increasing amplitude or 
pulse duration will produce larger droplets. 
Apart from the dispenser, the DSA system consists of a camera to record the droplet 
at the side, a mechanical stage which can move automatically in x- and y- directions 
accordingly and a light source (Figure 2.1d). 
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Figure 2.1: a) Photo of the dispenser used in the experiments, b) schematic diagram of the piezoelectric 
dispenser manufacture c) schematic graph of the operation principle of piezo-driven dispenser d) DSA 
100 system. 
2.2 Micro array printer 
A Scienion sciFLEXARRAYER piezo system (BioDot, Germany) was used in this work, is 
a non contact liquid handling and spotting system. The technology dispenses with a 
high dynamic volume range (picolitre to microlitre) and can accurately aspirate and 
dispense aqueous and organic solutions. Using the piezo-elements, spot volume can 
be changed as well as dispensing reagents on top of each other without 
contamination. 
This configuration uses a solenoid nozzle that is synchronized with a positive 
displacement of the syringe to dispense drops at frequencies in the range of 20-1000 
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Hz to dispense non-contact drops on a continuous base. This quantitative non 
contact technology couples the BioDot "drop-on-demand" valve with a high 
resolution syringe pump to meter precise amounts of reagent. 
The system consists of the liquid handling station, wash station, the dispenser and 
the dispense control system. The liquid handling station pumps the solution to the 
capillaries (nozzles) by a syringe pump using Teflon or PEEK tubes (Figure 2.2) . The 
flow of the liquid system is controlled via the 3/2 way valve. For aspiration the valve 
is in the first position and the syringe pump is moving down. After taking up a certain 
volume the valve switches to position 3 to push the aspirated volume into the 
system liquid bottle. For flushing the tubes with the system liquid the valve switches 
to position 3 first and the syringe pump soaks up the system liquid. The valve is 
changed to position 2 and the syringe pumps the liquid out of the dispenser capillary. 
The sample can be taken up by positioning the nozzle is in the sample solution, the 
3/2 way valve is switched to position 2 and the syringe pump starts aspiration. After 
the required uptake volume is completed, the valve will be switched to position 3 
and the syringe pump will move to the default position which is in the middle of the 
syringe . The uptake will be stopped by changing the valve to position 1 and lifting the 
nozzle above the sample solution. 
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Figure 2.2: Schematic diagram of the liquid handling [83] . 
The wash station comprises one independent, chemically inert wash channel for 
each dispenser nozzle, supplied by a peristaltic pump using separate, chemically inert 
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tubes. The inside of the nozzle is automatically cleaned with the system liquid when 
flushed . The outside of the nozzle is additionally cleaned in the wash station via a 
wash command. During the wash, the piezoelectric elements ultrasonicate each 
dispense capillary individually, for maximum wash efficiency. The wash station is also 
served by a two channel peristaltic pumps. The wash solution is put in a large flask 
and a filter is placed before the uptake tube. This tube can be split into several tubes 
depending on the number of nozzles installed. After the wash procedure, the waste 
from all channels is combined in one single pass through the wash station and taken 
away by one wash out tube, connected to the waste container. 
The dispense head can accommodate up to eight piezo dispense nozzles which each 
controlled individually. The dispense control station includes high resolution optical 
measurements, a stroboscopic LED for image illumination and a video camera . The 
camera is situated closed to the nozzle for visual inspection of the drop formation 
(Figure 2.3). The selected nozzle dispenses drops with its fixed frequency. The LED for 
image illumination is triggered by the piezo frequency, but it flashes at a user 
definable delay and hence the image can be captured at any point of the trajectory. 
This allows monitoring and optimization of drop size, drop velocity and drop 
trajectory. 
Figure 2.3: Photo of the dispense head and the camera [83] . 
The nozzle consists of a glass capillary with an outer diameter of 1 mm. This glass 
capillary is embedded into a piezo ceramic material, which is cemented onto the 
capillary. Most of the inner and outer surface of this piezo ceramic tube is an 
electrode to which a rectangular voltage pulse is applied . The ceramic contracts 
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while the voltage is applied initiating a pressure wave towards the glass capillary and 
towards the system liquid within the capillary. 
The stage comprises two magnetic linear servo drives (Figure 2.4) . A high resolution 
optical encoder continuously controls the motion of each driver. 
Figure 2.4 : Photo of the stage showing t ranslation axes [83] . 
2.3 Atomic Force Microscopy 
AFM is an imaging and force measurment technique which can visualise surfaces to 
the micrometre and nanometre scale. Figure 2.5 illustrates a schematic diagram of 
an AFM. It consists of a sharp tip which is scanned over a surface with a feedback 
mechanisms that enables the piezo-electric scanners to maintain the tip at a 
constant force (to obtain height information), or height (to obtain force information) 
above the sample surface [84] . As the tip scans the surface of the sample, moving up 
and down with the contours of the surface, the laser beam is deflected off the 
attached cantilever into a quadrant element photodiode. The photodetector 
measures the difference in light intensities between the upper and lower 
photodetector quadrants to determine the degree of cantilever flexure. Feedback 
from the photodiode difference signal, through software control from the computer, 
enables the tip to be maintained at either a constant force or constant height above 
the sample. In the constant force mode the piezo-electric transducer monitors real 
time height deviation. In the constant height mode the deflection force on the 
sample is recorded . The latter mode of operation requires calibration parameters of 
the scanning tip to be inserted in the sensitivity of the AFM head during force 
calibration of the microscope. 
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AFM can obtain topographical images in either contact mode (as described) or in 
tapping mode. In tapping mode the cantilever oscillates at its resonant frequency 
making intermittent contact with the surface. As the oscillating cantilever contacts 
the surface, the cantilever oscillation is necessarily reduced due to energy loss 
caused by the tip to the surface. The reduction in oscillation amplitude is used to 
identify and measure surface features. Typically, tapping mode is operated in a 
constant amplitude mode, whereby the feedback signal controls the height of the 
cantilever to maintain a constant user-set amplitude [85-86) . 
Apart from topographical information, AFM can provide details on the local 
compositions of the sample. There are many modes that can be used to achieve this 
[87-89], but the most common is to monitor the phase shift of the oscillating 
cantilever in tapping mode [90) . Such 'Phase imaging' can be used to detect 
nanoscale variation in composition, adhesion, friction, viscoelasticity, and other 
properties of the materials [86, 91). Changes in the phase lag often indicate changes 
in the properties of the sample surface. Phase imaging has been proved an extremely 
useful tool for pharmaceutical characterization. Phase imaging has been used to 
reveal polymeric forms from single crystal measurements [92), to confirm phase 
separation of two copolymers for drug delivery [93) and to identify formation of 
amorphous domains during miling of crystalline salbutamol [94). Other applications 
of AFM in pharmaceuticals concern the surface morphology [95-96], porosity [97), 
hardness [98) and surface energy [98-99) of drugs and excipients. 
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Figure 2.5: Schematic diagram of the main components of an Atomic Force Microscope. 
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2.4 Localised Thermal Analysis 
In localised thermal analysis (LTA), the sample is heated locally with a thermally 
active probe providing information about the glass transition temperature and the 
melting point of the sample at this location. LTA has proved useful for thin layers or 
coatings where bulk methods such as DSC, TMA and DMA cannot be applied [100]. 
Bulk methods measure the mean thermal properties of a sample, whereas L TA can 
provide information about the spatial distribution of the thermal properties of a 
material surface which can be useful to design materials with the desired properties. 
When the thermal probe is placed on the sample, the temperature of the tip is 
ramped linearly with time at a pre-defined rate while the degree of bending is 
monitored. At the point of phase transition, the material beneath the tip softens and 
the probe penetrates into the sample. This is reflected as reduction of the deflection 
whereby phase transition temperatures of the sample such as glass transition 
temperature or melting point can be determined. 
In this thesis, two different LTA methods scanning thermal analysis (SThM) and 
nanothermal analysis (NTA) were used. The main difference between these methods 
is the size of the probe. In SThM, the tip has a terminal radius of ca. SOOnm, whereas 
an NTA tip can be below lOOnm. In SThM a Wollaston wire probe is used. It consists 
of a silver wire with a fine platinum core which is bent into a sharp loop and etched 
to expose the core (Figure 2.6) [101]. This probe is relatively stiff and can be used in 
contact mode only. 
The NTA probes are fabricated from doped silicon by Anasys instruments (Santa 
Clara, CA) (Figure 2.7). These probes have a heater integrated into the end of the 
cantilever which allows them to be heated by the application of a current to around 
400' C at very rapid heating rates. Their advantages against the Wollaston probes are 
that they can achieve better spatial resolution and also they can image in both 
contact and tapping AFM modes and hence are more suitable for softer easily 
damaged samples. 
LTA has been successfully applied to many aspects of the industry, such as in 
electronics, polymer and biology science. Moreover, this technique has been gained 
significant interest in pharmaceuticals. The main advantage of this technique is that 
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can distinguish different components in a drug dosage forms in situ with minimal 
sample preparation and high spatial resolution . Hence, SThM has proved to be a 
useful tool to discriminate polymorphic forms of drug [102] and the coating of a 
tablet and its core [103] whereas NTA has been implemented to characterise nano-
dispersed pharmaceutical systems to confirm their heterogeneity [104-105]. 
Figure 2.6: Schematic diagram of an SThM Wollaston tip [101]. 
Figure 2.7: SEM images of the nanothermal cantilever (left) and its probe [106] . 
2.5 Confocal Raman Microscopy 
2.5.1 Theory 
When monochromatic radiation is incident upon a sample then this light depending 
on its interaction with the sample may be reflected, absorbed or scattered in some 
manner. In the Raman technique, the scattering of the radiation is considered to 
extract information about the molecular structure of the samples. 
28 
2. Instrumentation 
Raman scattering is an inelastic scattering of photons. The scattered light consists of 
two types; one called Rayleigh scatter which is strong and has the same intensity 
with the incident beam, and the other called Raman scattering which is very weak 
(10.5 of the incident beam) . There are two types of Raman scattering; Stokes and 
anti-Stokes scattering. In Stokes scattering, photons are scattered at low energy. 
Since at room temperature the population state of a molecule is principally in its 
ground vibrational state, this is the larger Raman scattering effect. In anti-Stokes 
scattering, the scattered photon are scattered at a higher energy. 
The incident photons will thus interact with the sample molecules, and the amount 
of energy change (either lost or gained) by a photon will be characteristic of the 
nature of each bond (vibration) present. However, not all vibrations will be 
detectable with Raman spectroscopy, since if the vibration of the molecule does not 
change its polarizability the Raman band will be very low or zero . 
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Figure 2.8: Schematic diagram of t he different energetic levels of photons for Raman scattering. 
2.5.2 Raman microscopy 
A Raman microscope can offer a powerful non-destructive and non-contact method 
of spatially resolved sample analysis. 
A standard Raman microspectrometer consists of an excitation source, a microscope, 
a spectrometer and a detector. Raman microscopy can use various radiation sources 
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which can be applied from ultra violet to near infra-red. The spectrometer is used to 
narrow the pass bands. The most common detectors that have been used are CCDs. 
In a confocal Raman microscope, there are additional pinhole apertures, to reject the 
out of focus light. One aperture is placed between the laser and the objective and 
the other is placed at the image plane of the objective. The apertures block the light 
scattered from regions outside the focal plane of the objective. A schematic diagram 
of a confocal microscope is illustrated in Figure 2.9 [107]. The main advantage of the 
confocal Raman is that it enables a very small sample area or volume to be analysed 
- down to the micron scale. 
One of the most important applications that confocal Raman spectroscopy offers is 
the opportunity to chemically map and image of a sample. In this case, images are 
recorded point by point and line by line while scanning the sample through the 
excitation focus. Chemical imaging as an analytical tool has been favoured as a non-
destructive, non-contact and non-invasive technique. Chemical imaging offers the 
ability to simultaneously identify and quantify several substances within samples. 
There are a plethora of publications related to this issue [108-114]. For instance, 
Raman mapping gave the opportunity to investigate the distribution of ibuprofen in 
PVP [115] and Alprazolam to Xanax [113]. 
One of the main challenges we need to face is that this technique can be time 
consuming, especially for samples with low Raman scatter that are mapped with high 
spatial resolution. Moreover, mapping an area with a pOint laser source may be very 
time consuming, subject to the desired spatial resolution, because of the small size 
of the laser spot (typically 1-10 ~ m ) . . The problem of long acquisition time has been 
resolved by employing Principal Component AnalysiS (PCA) to analyse experimental 
Raman mapping spectra [112]. Other techniques have been used to reduce the 
acquisition time are line imaging [116] where the detector analyses the spatial and 
spectral dimensions simultaneously and a focal plane array where optical detectors 
are composed of several thousand elements forming a matrix of pixel. They enable 
thousands of spectra to be obtained simultaneously [117J. 
Another factor which increases the time to plot a chemical map and was a Significant 
factor here is the loss of focus of the laser beam. Samples with increased roughness 
can contribute to this effect (Figure 2.10). This can be resolved by using autofocus 
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technology where during the scan of the sample surface the focal point microscope 
objective is moving up and down to focus exactly at the sample surface [118] . 
Autofocus considers that at the maximum light reflection, the refractive intensity 
from the laser is also at a maximum. In practise, this may not be true and usually an 
offset must be set. When autofocus is employed the acquisition time per spectra 
increased to around 4 seconds. 
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Figure 2.9: A schematic diagram of Confocal microscopy. 
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Figure 2.10: Schematic image of the principle of autofocus where the end of the arrows indicate where 
the focus location . The left image represent the system working without autofocus where the laser only 
at the edge of the spot is focused . The right image represents the autofocus system where the laser 
beams are focused along the surface of the spot. 
2.5.3 Extraction of distribution maps 
Chemical images can be produced from the acquired spectra (with tagged spatial 
coordinates) in various ways. The simplest option is to follow the intensity or the 
area under a certain peak which is characteristic for a compound . This so-called 
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univariate approach is used whenever possible because it is the simplest and most 
understandable way to produce chemical images, one for each component. 
However, the condition that all the components of the imaged sample have uniquely 
assignable wave numbers with satisfactory signal-to-noise (s/n) ratio is not always 
fulfilled. Additionally, mapping an area may be demanding because of the small size 
of the laser spot (typically between 1 - 1 0 ~ m ) ) and also because of the high acquisition 
time required to increase the s/n ratio [111J. Moreover, in more complex systems 
where the specific peaks can be overlapped or a constituent compound is at a low 
concentration then univariate analysis cannot extract reliable distribution maps, and 
hence more advanced data analysis tools are used. Multivariate curve resolution has 
been shown to be very effective for unravelling complex spectral data from mapping 
(or imaging) Raman data. 
Multivariate analysis takes into account aU the spectrum information. The most 
common multivariate methods for imaging data analysis include principal 
component analysis (peA), and partial least square (PLS). These methods aim to 
unravel the pure spectra of the compounds and their concentrations from mixed 
spectra. They are based on the assumptions that the signal collected is linearly 
related to the concentration of the components. Thus, the mixed spectra can be 
expressed as the sum of each pure material spectrum plus the experimental noise. 
The spectrum set of a mixture containing k compounds can be mathematically 
expressed, if the interactions among the constituents are negligible, with the 
following equation. 
x=csT +E 
Where ST (kxA) is the pure spectra matrix, consisting of A wavenumbers, k is the 
number of samples. X (pxA) is the matrix containing the mapping spectra which is 
equal to the numbers of samples x number of wavenumbers and C (pxk) is the 
concentration matrix of the components (number of samples )( number of 
components). The matrix E represents the residual noise. In effect, PCA decomposes 
the data into sections of signal and noise. By removing the noise, the Signal to noise 
ratio (s/n) can be significantly improved. The major results that PCA provide are the 
number of components that have detectable signal, the features that are related to 
the signal and the features that are related to the concentration [119]. It should be 
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noted that the data is originally acquired in a three-dimensional hypercube form 
(nxmxA), thus, the data has to be unfolded into a two dimensional matrix 
beforehand. Every mapping data set is a 3D data structure (two spatial dimensions 
and one spectral) which can be temporarily rearranged by appending two spatial 
coordinates to produce a 20 data structure (one spatial and with mixed with x- and 
y- coordinates and one spectral dimension (Figure 2.11). peA is applied to this 20 
data structure and, after completion of the 20 results, scores are folded back into 
the original 30 data sets from which then chemical images are then produced. All the 
procedure mentioned before is employed to all multivariate studies of Raman 
spectra. 
If the pure spectra matrix is available, the direct classical least square (OCLS) can be 
used. In this case the spectral concentrations are estimated by: 
Other techniques involve clustering techniques, and multivariate curve resolution 
(MCR) [108]. 
Zhang et 01. described theoretical multivariate methods of analysis applied to a 
model a pharmaceutical tablet. From all the techniques, OCSl was considered to 
provide the most reliable results since it is based on reference spectra. PCA was 
described as an exploratory data analysis technique. In general, there is not a one to 
one correspondence between a principal component and a chemical compound but 
in some formulations it is possible that a PCA loading matches a pure reference 
spectrum. Cluster analysis has been shown that it is a useful tool to segment a data 
set into regions of similar chemical composition or physical form. It is a useful tool to 
characterize a product with distinct spatial distribution character. Finally, MCR 
provided similar results with the OCLS. However, its interpretation should be with 
caution as a particular component spectra may have the signature ofthe other [108J. 
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Figure 2.11: Schematic representation of a spectral imaging hypercube showing the relationship 
between spatial and spectral dimensions [117] . 
2.6 Attenuated Total Reflectance Spectroscopy (ATR) 
ATR-FTIR is a method of performing spectroscopy on a solid sample to detect the 
frequencies of IR radiation absorbed by the material. In ATR spectroscopy, an 
infrared beam is directed onto an optically dense crystal with a high refractive index 
at an angle greater than the critical angle to internal reflection. This internal 
reflectance creates an evanescence wave that extends beyond the surface of the 
crystal into the sample held in contact with the crystal. This evanescent wave 
protrudes only a few microns (0.5 11 - 5 11) beyond the crystal surface and into the 
sample. Consequently, there must be good contact between the sample and the 
crystal surface. In regions of the infrared spectrum where the sample absorbs 
energy, the evanescent wave will be attenuated or altered . The attenuated energy 
from each evanescent wave is passed back to the IR beam, which then exits the 
opposite end of the crystal and is to a detector in the IR spectrometer. The system 
then generates an infrared spectrum. 
The most popular ATR crystal analysis materials are zinc selenide (ZnSe) and 
diamond. Both of these crystals have a refractive index of 2.4. A typical polymer 
refractive index is 1.5. At 45 degrees angle of incidence and at a wave number of 
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1000 cm-l the ATR depth of penetration would be about 2 microns. The most likely 
differentiation for use of ZnSe or diamond is the form and hardness of the polymer 
sample . The Knoop hardness (kgjmm 2) of diamond is 8820 whereas that of ZnSe is 
120.5. In practical terms this means that for softer or for flat polymer samples a ZnSe 
ATR crystal is used. 
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Figure 2.12: Schematic diagram of the principal ATR-FTIR spectroscopy 
• 
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3. Production of individual 
sprayed formulations 
3.1 Introduction 
In this chapter, the first step towards the formulation of medicines via inkjet printing 
is demonstrated. APls along with excipients have been dissolved in appropriate 
solvents and sprayed on to hydrophobic treated glass slides. The chosen APls were 
felodipine, captopril and hydrochlorothiazide. 
Felodipine dispersed in PVP is an extensively studied poorly soluble drug system [34, 
120-129]. Typically the compounds are dissolved in alcohol, followed by rapid 
evaporation of the solvent to produce an amorphous single phase material with 
improved dissolution properties compared to crystalline felodipine. To prove this 
inkjet method, we compared the product to the published bulk methodologies for 
producing dispersions. 
Captopril and hydrochlorothiazide have been chosen as a combination therapy used 
commercially (Capozide™) that the inkjet printing can reproduce in a microarray 
format. Hydrochlorothiazide is practically insoluble in water, whereas captopril is 
freely soluble in water. 
The deposited products were characterized using Atomic force microscopy (AFM), 
scanning thermal microscopy (SThM) and nanothermal analysis, attenuated total 
internal reflection infra red spectroscopy (ATR-IR) and Confocal Raman microscopy 
(CRM) to provide complementary characterisation. In particular the release profile of 
the drugs was studied to assess the potential of the format for therapeutic purposes. 
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3.2 Active Pharmaceutical Ingredients 
3.2.1 Felodipine 
Felodipine is an oral calcium- channel blocker (CCB) of the dihydropyridine (DHP) 
class. Calcium is necessary for muscle cells to contract. Felodipine prevents calcium 
from being released within the muscle cells of the small arteries and thereby causes 
the muscles to relax and the arteries to dilate or expand. It is a well tolerated drug 
which is a given in an extended release tablet formulation where a single dosage can 
last for 24 hours [130]. Felodipine is marketed under the brand 
name Plendil™ by AstraZeneca and Renedil™ by Sanofi-Aventis. 
3.2.1.1 Fe/od/pine's formu/otion 
Felodipine has been investigated extensively. As a compound practically insoluble in 
water, its in-vivo bioavaiJabilitv can become limited. Dissolved felodipine can be 
completely adsorbed from the gastrointestinal tract so solubility can be a limiting 
factor to bioavailability. Hence, the concerned research mainlv focuses on the 
improvement and modification of the release profile. The first solid dosage form was 
a conventional tablet which is clinically effective in a twice daily dosage. Along with 
the conventional release tablets, extended release has been prepared which require 
one dosage. Both the formulations have equal bioavailability [131]. 
Usually, to produce a controlled drug release profile of felodipine, it is mixed with a 
hydrophilic excipient, to form a uniform mixture. The most common excipients that 
have been used are PVP [31, 34, 121-129, 132], HPMC [31, 34, 123-125, 129], PEG 
[120, 132] and some polymeric surfactants [133]. In most of the cases, the drug and 
the excipient have been dissolved in an appropriate solvent (e.g. ethanol), followed 
by a rapid evaporation to produce an amorphous product. 
Dissolution studies have shown that the use of a hvdrophilic excipient can enhance 
the dissolution of felodipine, improving its bioavailability {124-125]. 
3.2.2 Captopril 
This drug belongs to a group of medications called ACE inhibitors. It is used to 
treat high blood pressure (hvpertension). It works bV relaxing blood vessels, causing 
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them to widen. Lowering high blood pressure helps prevent strokes, heart attacks 
and kidney problems. This medication is also used to improve survival after an 
acute heart attack, to help protect the kidneys from damage due to diabetes, and 
with other drugs (e.g., "water pills"/diuretics, digoxin) to treat congestive heart 
failure. 
Captopril is commonly marketed by Bristol-Myers Squibb under the trade 
name capoten™. 
3.2.2.1 Captoprll's /ormulaUon 
The drug is freely water soluble and has an elimination half-life after an oral dose of 
1.7 h. It is stable at pH 1.2. As pH increases, the drug becomes unstable and 
undergoes a degradation reaction. More specifically, above pH 4 the rate of captopril 
degradation increases with pH, whereas below pH 4 the rate of degradation is 
independent of pH [134].The efficacy of Captopril after oral dosing lasts for only 6-
Shours. Therefore, clinical use requires 37.5-75 mg to be taken 3 times daily. The 
development of oral controlled release formulations for captopril is difficult because 
of in vivo and in vitro instability. The drug also undergoes dose dumping and burst 
phenomenon (being freely water soluble) when formulated as controlled or 
sustained release formulation. Development of a prolonged-action dosage form 
of captopril should bring many benefits to patients for the following reasons: (1) a 
decrease in the frequency of administration should lead to an improvement in 
patient compliance and as a result clinical efficiency would be improved; (2) it is 
expected that a minimization of fluctuations in the blood concentration of the drug 
will decrease the risk of side-effects [135]. 
Various approaches have been used to develop a prolonged release oral dosage 
forms. These can involve the use of polymers as fillers or coatings in the preparation 
of tablets, pellets and matrices. Seta et 01. have studied prolonged-action dosage 
forms of captopril using seven different formulations, including coated slow-release 
granules, enteric coated granules, an oily semisolid matrix (OSSM) and four kinds of 
modified release tablets [136]. A sustained release captopril formulation has also 
been reported by Serajuddin et 01. which was a capsule dosage form 
containing captopril and a semi-solid matrix of at least one fatty acid glyceride 
and/orpolyethylene glycol ester {137]. Abramowitz et 01. designed a formulation 
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where captopril is inside a polymeric core which is coated with an enteric polymers 
such as methacrylic acid copolymers, hydroxyl propyl methyl cellulose phthalate 
(HPMCP) and cellulose acetates or delayed release coating such as ethyl cellulose 
and methacrylic acid copolymers [138]. Granulated excipients of lactose or dicalcium 
phosphate with ethylcellulose were examined for their ability to be used as matrix 
materials to produce a controlled release dosage form by direct compression for 
captopril [139]. 
3.2.3 Hydrochlorothiazide 
Hydrochlorothiazide (HCT) is a diuretic. It increases the amount of urine passed, 
which causes the body to lose salt and water. This medicine is used to treat high 
blood pressure. It is also reduces the swelling and water retention caused by various 
medical conditions, such as heart, liver, or kidney disease. 
Hydrochlorothiazide is sold both as a generic drug and under a large number of 
brand names, Apo-Hydro™, AquazideH™, Dichlotride™, Hydrodiuril™, 
HydroSaluric™, Microzide™, ESidrex™, and Oretic™. 
Hydrochlorothiazide is also used in combination with many common drugs used to 
treat hypertension such as Diovan HCT, Zestoretic, Benicar HCT, Atacand HCT, 
and Lotensin HCT and others. 
3.2.3.1 ConvenUonal/ormulations 0/ Hydrochlorothiazide 
Hydrochlorothiazide has limited solubility in water which can reduce its 
bioavailability. The main method to increase its bioavailability is to incorporate it 
within hydrophilic polymers. Verveat et 0/ demonstrated that the incorporation of a 
liquid solubiliser into microcrystalline cellulose pellets enables the enhancement of 
the release of the HCT. Also, PEG 400 and PVP has been applied to increase the 
bioavailability [140-141]. Furthermore the dissolution enhancement by preparing 
solid dispersion formulation with PVP has been studied. 
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3.3 Aims - Objectives 
The aim of this chapter is to describe the production and testing of formulations of 
felodipine, captopril and hydrochlorothiazide as APls using inkjet printing. The APls 
were combined with appropriate polymers to achieve the desired properties of the 
final formulation. The compounds were dissolved in appropriate solvents and the 
solutions were sprayed using a piezo driven dispenser. The dried products were 
subsequently analyzed using micro- and nano- analytical methods for the physic-
chemical state and drug release properties. 
3.4 Materials - Methods 
3.4.1 Materials 
Felodipine was supplied by AstraZeneca (Charnwood, Leics., UK). Captopril, 
Hydrochlorothiazide (HCT), Polyvinyl pyrollidone (PVP) k30, poly(lactic-co-glycolic 
acid) (85:15), Pluronic F-127 and DMSO 99% anhydrous were purchased from Sigma-
Aldrich. Flutec fluid was purchased by F2 chemicals (Lancashire, UK). 
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Figure 3.1: Felodlplne Figure 3.2: Captopril Figure 3.3: Hydrochlorothiazide 
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Figure 3.4: PVP K30 Figure 3.5: PLGA Figure 3.6: Pluronic F-127 
(n = number of monomers (x: number of Lactic Acid units (a/b/a/ = 130/80/100) 
MW=30000) y: number of Glycolyc Acid units 
xly = 85/15) 
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3.4.2 Methods 
3.4.2.J Preparation of solutions 
Feladlplne 
Solutions of felodipine and PVP were prepared by dissolving them into a mixture of 
ethanol and DMSO (95/5). Felodipine is soluble in ethanol. DMSO was used to 
increase the boiling point of the solution to reduce chances of the dispenser clogging 
due to the evaporation of the solvent. The ratios of felodipine to the polymer were 
1/10, 1/5, 1/2, 1/1 and 2/1 (w/w). 
Caproprll 
Solutions of captopril and PLGA were prepared by dissolving them into a mixture of 
chloroform, ethanol and DMSO (75/18/7). Chloroform was also used to dissolve 
PLGA. Ethanol was used to dissolve captopril and to disperse DMSO, as DMSO is not 
miscible with chloroform. Finally, DMSO was used to increase the boiling point to the 
solution to avoid any possible clogging of the dispenser. The ratios of captopril to the 
polymer were 30/70 and SO/50 (w/w). 
Hydrochlorothiazide 
Solutions of hydrochlorothiazide with PVP and PLGA were prepared. When PVP was 
used, the compounds were dissolved into a mixture of acetone, ethanol and DMSO 
(55/38/7). Acetone was used to dissolve HCT, ethanol to dissolve PVP and DMSO to 
increase the boiling point of the solution. 
In the case of PLGA, the compounds were dissolved into a mixture of acetone, and 
DMSO (93/7). Both HCT and PLGA are soluble in acetone. DMSO was used to increase 
the boiling point of the solution. 
3.4.2.2 Preparotlon of surface 
Hydrophobic surfaces suitable for retaining the sprayed micro-droplets were 
prepared by depositing f1utec fluid on glass cover slips using a spin coating device. 
Flutec fluid is a fluorinated compound (4-pentafuorosulfurnitrobenzene). The 
hydrophobic surface was to avoid the spreading of the samples after their 
deposition. 
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3.4.2.3 Dispensing 0/ solutions 
All the solutions were ejected as pico-litre droplets using a piezo driven dispenser 
(GeSim A010-201 PICPIP). The solvent was evaporated under ambient conditions and 
the samples were kept in a desiccator until further analysis. The duration and the 
amount of voltage and the frequencies of cycles applied to the piezo dispenser were 
used to control droplet deposition. In general, the sprayed conditions were 
determined by the surface tension and viscosity of the solution. Solutions with higher 
viscosity required a higher voltage, whereas surface tension is the predominant 
factor which affects the droplet formation [71]. Here the optimum voltage for the 
samples for a single droplet was found to be in the range of 35 - 42V applied in 35 -
45 ",sec pulses. 
At this point, it is worth noticing that when PVP and felodipine were used as solutes 
in the sprayed solution, the nozzle was clogged in very few seconds (Figure 3.7), even 
though the solutions were stable in the vials after weeks of their preparations. This 
phenomenon was deteriorated increasing the concentration of solutions. 
Unfortunately, it was not clear whether this was happening in the higher 
concentration of felodipine or PVP. An explanation of this can be lying behind the 
chemical structure of PVP. PVP as it contains hydrophilic groups and a hydrophobic 
chain can act as a surfactant. Hence, it was possible that if there were bubbles in the 
solutions, PVP could cover them and the felodipine may precipitate there. A similar 
phenomenon was observed by Schubert group where when they used solvents 
containing amino groups the solution with polystyrene, the polymer was precipitated 
inside the nozzle in a couple of seconds. This group was not able to justify the reason 
[60]. 
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Figure 3.7: photo of the clogged piezo-dispenser. 
3.4.2.4 Atomic Force Microscopy (AFM) 
AFM analysis was performed in air using tapping mode with a Dimension 3000 
(Nanoscope lila controller, Veeco, CAl . Tap300 cantilevers were used (Budget 
Sensors, Sofia, Bulgaria). The images where analyzed using the SPIP software (Image 
metrology, Denmark) . 
3.4.2.5 Thermal Analysis 
Nanothermal Analysis (NTA) 
NTA was performed on single dried droplets using a Multimode AFM (Nanoscope V 
controller, Veeco) with a NTA modification from Anasys Instruments (Santa Barbara, 
CAl . The probes used were AN2 (Anasys) with heating rate of 1°C/sec. The 
instrument was calibrated using measurements on poly(caprolactone) (PCl) (Tm = 
55°C), polyethylene (PE) (Tm = 116°C) and polyethylenetelephalate PET (Tm = 238°C). 
Scanning Thermal Microscopy (SThM) 
SThM analysis was performed using an Explorer AFM system (Veeco) with a 
Wollaston wire micro-thermal tip (Veeco). To increase the signal level samples were 
produced with 40 droplets to increase the mass of material for analysis. 
In the case of felodipine, local thermal analysis was performed with a temperature 
ramp rate of lOoC/sec. The same calibration samples as for NTA were employed. 
Finally, the theoretical glass transition temperature of the mixture based on the 
Gordon-Taylor (GO) equation [142] were compared with the measured values. This 
43 
3. Production of individual sprayed formulations 
equation assumes that the two components are miscible. The GO equation is defined 
as 
(3.1) 
PiT, The constant k is defined as k = --g-
P 2Tg2 
(3.2) 
Where Wl, Wz, Tgl and Tg2 are the mass fraction and the glass transition of felodipine 
and PVP respectively and Pl and P2 the densities of felodipine and PVP. According to 
Konno et 01. these are equal to 1.33mg/ml and 1.28 mg/ml respectively [123]. 
The value of glass transition temperatures of the PVP and felodipine that has been 
used to determine the constant k for each compound and the glass transition 
temperature were based on the SThM data. For PVP and felodipine these were equal 
to 198 DC and 46 DC respectively. 
In the case of HCT/PVP system the density of HCT was from Tajber et 01. and was 
equal to 1.89 mg/ml [143]. 
3.4.2.6 Infrared Spectroscopy (ATR -IR) 
As for SThM, samples with multiple droplets were used to increase signal levels for 
ATR-IR. To avoid crystallization of the API, the solvent was evaporated in vacuum. 
The IR spectra were obtained using a Nicolet Avatar 360 FTIR using diamond as 
crystal. 
In the case of felodipine the number of scans was 200 over the range 450 - 4000 cm·l 
at a resolution of 4cm·1• For captopril and HCT, the IR spectra the number of scans 
was 1000 over the range 450 - 4000 cm· l at a resolution of 4 cm-1• 
3.4.2.7 Confocal Raman 
Confocal Raman studies were performed on single droplets using a Jobin-
Yvon/Horiba micro-Raman spectrometer, by means of red laser with 632nm 
wavelength and 600 l/nm grating. The spectrometer is equipped with an Olympus 
microscope BX41. 
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In all the cases, Raman spectra were obtained on multiple droplets with l 0 0 ~ m m slit 
width, 8 sec acquisition time. Each spectrum was the mean of four measurements. 
In terms of the Raman mapping, when felodipine was applied as an API, the 
experimental conditions were a l 0 0 ~ m m slit width, a l00x microscope objective and 
5sec exposure time. Each spectrum was the mean of two measurements. The sample 
profiling was performed at step increments of l ~ m m in x- and y- directions. 
For felodipine/PVP and HCT/PVP the confocal Raman mapping was performed on a 
single droplet. The sample profiling was performed at step Increments of l ~ m m in x-
and y- directions. 
For captopril/PLGA, HCT/PLGA and HCT/PLGA/Pluronic the Raman mapping has been 
performed in multiple droplets. The sample profiling at step increment in these case 
were performed on 5 ~ m m in x- and v- directions with 0.5 sec exposure time. Each 
spectrum was the mean of two measurements. The slit width was 150 ~ m . .
All the Raman studies were carried out through l00xmagnification lense. The 
chemical images were then constructed based on algorithms of the NGLabspec 
spoftware (Horiba Jobin Yvon). The eigenvalues of each principal component was 
calculated using Solo+MIA software (eigenvector, USA). 
3.5 Results 
3.5.1 Atomic Force Microscopy 
3.5.1.1 Fe/adlplne 
AFM imaging of single droplet felodipine/PVP spots at the different ratios showed 
them to be homogenous at the nanoscale with no indication of drug crystallization 
and phase separation (Figure 3.8a, c, d, e, f). Although small holes can be observed in 
the film due to the drying phase the material deposited shows no evidence of 
internal structure. Intimate mixtures with PVP therefore appear to inhibit 
crystallization of felodipine as has been shown previously for bulk formulations. 
However, at the higher concentration of PVP small crystals can be formed which 
45 
3. Production of individual sprayed formulations 
must come from PVP's crystallization (Figure 3.8b) . Due to the rapid evaporation of 
the solvent from such small drops, the felodipine deposited alone also appears to 
have no internal structure and therefore is likely to be amorphous (Figure 3.8a) . 
However, when the dispenser sprays for more than a minute, crystals are formed 
which is caused by the slower evaporation of the solvent from such a large volume 
(Figure 3.8g) . 
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Figure 3.8: AFM topographic (left) and phase (right) images of the surface of a) sprayed felodipine and 
felodipine/PVP micro-deposits at ratio b) 1/10, c) 1/5, d) 1/2, e) 1/1, f) 2/1 and g) a product produced 
by spraying mUltiple droplets of felodipine/PVP " 1/10 (w/w) . 
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3.5.1.2 Capropril 
The product obtained when captopril and PLGA of different ratios were sprayed is 
illustrated in Figure 3.9 When PLGA was sprayed alone the deposits appeared 
amorphous and homogenous (Figure 3.9a). However, the addition of captopril 
resulted in the formation of small dots on the surface. These dots are likely to be 
captopril exposed on the surface (Figure 3.9 b,c). 
Figure 3.9 : AFM topographic and phase (right) AFM images of a) sprayed PLGA and captopril/PLGA 
mixtures at b) 30/70, c) SO/50, w/w ratios and d) after the dissolution of captopril/PLGA mixture in 
water for 5 sec. 
48 
3. Production of individual sprayed formulations 
3.5.1.3 Hydrochlorothiazide 
When hydrochlorothiazide was sprayed with PVP, the product was homogenous 
without any sign of phase separation or crystallization (Figure 3.10). As in the case of 
felodipine, small holes can be observed which are due to the drying phase of 
material deposited (Figure 3.lOb and d) . 
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Figure 3.10: Topographic and Phase (right) AFM images of a) sprayed HCT and HCT/PVP mixture of 
ratio b) 1/5, c) 1/2, d)l/l, e) 2/1 . 
When PLGA is used although the product is amorphous there is a phase separation of 
the two compounds. This is identified in the phase image where certain areas appear 
bright in the phase contrast (Figure 3.11). 
Figure 3.11: Topographic and Phase AFM image of HCT/PL:=t- = 3:/ : \:/.::. 
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3.5.2 Localised Thermal Analysis 
3.5.2.1 Fe/odipine 
SThM and NTA raw data are presented in Figure 3.12. Only one Tg was observed for 
each mixture which is consistent with a true solid dispersions being formed. It is clear 
that the NTA and the SThM produced comparable results. As the drug concentration 
increased the Tg was reduced . The values predicted from the Gordon-Taylor equation 
(fig. 4) are lower than the experimental values, indicating that either the sample 
does not ideally match the assumptions of this model (e.g. complete miscibility of 
the two components) or that the thermomechanical properties of the samples are a 
contributory factor to the experimental measurements. A more thorough analysis of 
how the properties of the samples and tip are represented in the discussion section 
in th is chapter (discussion 3.6.1). 
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Figu re 3.12: Comparisons Tg f rom SThM, NTA and the Gordon-Taylors equation fo r Felodipine-PVP 
mixtures. 
3.5.2.2 Hydrochlorothiazide 
SThM data of HCT/PVP mixture are represented in Figure 3.13. The experiment 
revealed a single glass transit ion point which is consistent with an intimate mixture 
of the API and the polymer. As the drug concentration increased, the observed Tg 
reduced . Also, the values predicted from Gordon - Taylor are lower than the 
experimental values as for the felodipine/PVP system. 
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Figure 3.13: a) Comparison the data from SThM and Gordon - Taylor equation . 
3.5.3 Infrared Spectroscopy (ATR-IR) 
3.5.3.1 Feiodipine 
ATR-IR was used to examine the intermolecular interactions between felodipine and 
the polymer in the spot formulations. Felodipine has a secondary amine group that is 
capable of forming hydrogen bonds with the carbonyl groups of PVP and with the 
carbonyl group of other felodipine molecules. The characteristic wavelength range 
for the evaluation of these interactions is at the -NH stretching region between 3000 
and 3700 cm·l . If this -NH group interacts with the carbonyl group, its associated 
peak shifts to a lower wavenumber. Hence, for the crystalline drug powder one 
single peak is observed at 3344 cm·l , but in the sprayed felodipine the peak is moved 
to lower wavenumber at 3324 cm·l indicating that the hydrogen bonding among the 
felodipine's molecules are stronger in the amorphous sprayed drug as it has been 
previously reported (Figure 3.14c) [123, 126J. Additionally, there is simultaneous 
change in the carbonyl region (Figure 3.14b). Specifically, the carbonyl peak of the 
sprayed drug has been split in two peaks from which the former has been moved to 
higher wavenumbers at 1699 cm·l compared to the crystalline powder, whereas the 
latter has been shifted to lower wavenumbers at 1688 cm·l . This indicates that as 
there is only one peak that has been moved downwards, only one of the carbonyl 
groups is associated with the hydrogen bonding, whereas the other either does not 
compete at all or its energy is very low. 
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In the formulations with 2:1, 1:1 and 1:2 drug to PVP ratio the peak corresponding to 
the NH group is split and appears at lower wavenumbers (Figure 3.14c). This has 
been proposed to indicate a stronger hydrogen bonding between the felodipine and 
the polymer than with itself. When higher concentrations of PVP are used the -NH 
group is obscured by the large water peak is associated with the highly hygroscopic 
PVP rendering analysis difficult. Finally, it is worth noticing that the broadness of the 
peak is consistent with the proposed amorphous nature of the product, as the peak 
in question of crystalline powder is sharper. 
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Figure 3,14: a) ATR spectra of powder felodipine, sprayed felodipine, PVP and mixtures of 
felodipine/PVP of various ratios, b) ATR spectra of sprayed felod ipine and powder felodipine in the 
carbonyl reg ion c) ATR spectra of powder felodipine, sprayed felodipine and mixtures of felodipine/PVP 
of various ratios in the NH reg ion, 
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3.5.3.2 Captoprll 
ATR spectra of Captopril powder and sprayed captopril are illustrated in Figure 3.15. 
The peaks at 1749 and 1589 cm-1 corresponds to the C=O group of carboxylic acid 
and amide. The peaks at 1228cm-1 and 1220cm-1 corresponds to the c-o and C-N 
bending vibration. 
By comparing the ATR spectrum of the powder captopril and the sprayed captopril in 
the CO region (Figure 3.15b), it is clear that the peak corresponding to the C=O group 
of carboxylic group has been moved towards lower wavenumbers, whereas the 
broadness of the amide peak in the sprayed product does not allow identifying the 
peak shift. 
Also, by applying ATR any possible interaction between the captopril and PLGA could 
be investigated. Captopril could be bonded with PLGA by hydrogen bonding either of 
its carbonyl groups with the OH group or of the SH group with the C=O group of 
PLGA. However, ATR does not seem to confirm this as the carbonyl peaks of PLGA in 
the captopril/PLGA mixture and in the sprayed PLGA remain in the same position 
(Figure 3.15c) 
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Figure 3.15: a) ATR spectra of PLGA, crystalline captopril, sprayed captopril and the mixture 
captopriljPLGA of various ratiOS, b) comparison of ATR spectra of sprayed Captopril and crystalline 
powder of Captopril in the co region, c) comparison of ATR spectra of sprayed Captopril, crystalline 
powder and mixture of Captopril PLGA mixture. 
3.5.3.3 Hydrochlorothiazide 
In Figure 3.16a the ATR-FTIR spectrum of the crystalline powder, the sprayed HeT 
and the mixtures of HCT/PVP of various is illustrated. The most important chemical 
groups of HeT molecule are the four amino groups and the s=o groups since these 
c) 
two groups can interact either with other HeT molecules or with other potential 
excipients by means of hydrogen bonding. Specifically, HeT has four amino groups 
from which two are coming from the primary sulphonamide, one from the secondary 
sulphonamide and there is one secondary amino group. In the crystalline powder the 
peaks which correspond to the NH groups are at 3359 cm·l , 3262 cm-l and at 3166 
em-i. The symmetric stretching vibration of SO groups appeared at 1149 and 1163 
cm-1 whereas the antisymmetric stretching vibration of SO group is detected at 1317 
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cm·
l 
and 1333 cm·l • The strong peak at 1600 cm-l corresponds to the C=C group of 
the aromatic ring. 
In the sprayed HCT the peaks of the spectrum were broadened, an Indication of the 
amorphous nature of the product. The NH peak at 3166 cm-1 has been overlapped by 
the peak at 3262 cm-l (Figure 3.16b). In terms of the SO peaks the two peaks 
assigned to the asymmetric stretching vibration has overlapped each other to a 
broad intense peak detected at 1320 cm-1• The peaks corresponding to the 
symmetric SO vibration at 1149 and 1163 cm-l has been shift to 1154 and 1167 cm-l 
respectively (Figure 3.16c). Finally, the peaks correspond to the NH scissoring 
vibration have been shift from 1521 and 1555 cm- l to 1515 and 1553 cm-1 
respectively (Figure 3.16c). All the peak movements described above, It is an 
indication of a rearrangement of the hydrogen bonding in the sprayed material. 
ATR-FTIR has been Implemented to investigate the bonding between PVP and HCT. 
Figure 3.16d shows the comparison of the amorphous HCT with the 2/1 (w/w) 
HCT/PVP mixture. HCT has four NH groups which can be associated with the c=o 
group of PVP. It is illustrated that when PVP is added, then the two peaks of amino 
group are moved to lower wavenumbers due to hydrogen bonding between the NH 
groups of HCT with the carbonyl group of PVP. 
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Figure 3 016: a) ATR spectra of powder HCT, sprayed HCT, PVP and mixture of HCT/PVP of different 
ratios, b) comparison of powder HCT and sprayed HCT in the region of NH group c) comparison of 
powder HCT and sprayed HCT in the carbonyl region between 1100 cmol - 1700 cm ol d) comparison of 
sprayed HCT and HCT/PVP in the region of NH group. 
The ATR-FTIR spectrum of PLGA has also implemented to investigate any possible 
interactions between HCT and PLGA. HCT can be associated by means of hydrogen 
bonding not only between the c=o groups of PLGA and the NH groups of HCT but 
also between the 5=0 groups of HCT with the OH group of PLGA. The former bond 
could be detected by a peak shift of the carbonyl peak of PLGA and the NH peak of 
HCT. Figure 3.17b shows that the NH peak at 3258 cmol of the sprayed Hcr has been 
slightly shifted to lower wavenumbers in the mixture with PLGA. This is more obvious 
in the HCT/PLGA = 70/30 where the HCT signal is stronger due to its higher 
concentration. However, the peak of the carbonyl group of PLGA remained in the 
same position with the pure compound . Also the peak which corresponds to the 
asymmetric vibration of 50 has slightly moved to higher wavenumbers at 1328 cm ol 
from 1322 cm ol of the sprayed HCT (Figure 3.17c). 
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Figure 3.17: a) ATR spectra of powder HCT, sprayed HCT, PLGA and mixture of HCT/PLGA of different 
ratios, b) comparison of sprayed HCT and mixtures of HCT/PLGA of different ratios in the region of NH 
group c) comparison of sprayed HCT and HCT/PLGA mixtures in the sulphonic region from 900 cm·l to 
1600 cm·l . 
3.5.4 Raman 
3.5.4.1 Feiodipine 
From the Raman spectrum of felodipine crystalline powder, it has been observed 
that there is a characteristic peak at 3335 cm·l which corresponds to the NH 
stretching vibration and a characteristic peak at 1639 cm·1 corresponding to the free 
carbonyl stretching mode. In the sprayed felodipine the characteristic peak of NH 
group in addition to become broader losing lots of its intensity and moves towards 
lower wavenumbers indicating that the hydrogen bonding among felodipine's 
molecules are stronger than in crystalline powder (Figure 3.18). Also, in the samples 
where PVP is added the peak of amino group is disappeared, possibly due to the low 
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concentration of the felodipine. Also, the carbonyl group of the PVP is covered by the 
carbonyl group of felodipine . As the concentration of PVP increases, its characteristic 
peaks are increasing (Figure 3.19) . 
• fclodipine sprayed 
• felodipine powder 
'''''' . 
Figure 3.18: Raman spectra of powder felodipine and sprayed felodipine. 
____ ~ r r
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Figure 3.19: Raman spectra of sprayed felodipine, PVP and · mixtures of felodipine/PVP of various ratios. 
3.5.4.2 Captopri/ 
The Raman microscope spectra of the crystalline powder of captopril and the 
sprayed captopril are shown in Figure 3.20. In the captopril powder the c=o 
stretching vibration of the carboxylic group of captopril is assigned at 1745 cm·l and 
the C=O stretching vibration of the amide group at 1603 cm· l and at 1583cm-l , In the 
sprayed drug the former peak has been shifted to 1727 cm·l whereas the latter has 
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been shifted to 1616 cm·l . Moreover, due to the broadness of the peak, it is not clear 
if both the peaks of the amide of the crystalline have been shifted. 
Confocal Raman microscopy has been also implemented to investigate any possible 
interactions between the captopril and PLGA. The position of the characteristic peaks 
of captopril and PLGA is in the same position with their pure product indicating that 
the nature of the compounds remains the same and no interaction between them 
takes part (Figure 3.21). 
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Figu re 3.20: Raman spectra of powder captopril and sprayed captopril with zoom in the carbonyl region 
at 1550 -1800cm·1 . 
Figure 3.21: R; man spectra of sprayed c c ~ t ~ p r i i , , PLGA a ~ d d mixtures of Captopril/PLGA = SO/SO (w/w) 
mixture. 
3.5.4.3 Hydrochlorothiazide 
In Figure 3.22 the Raman spectra of HCT on various forms is illustrated. The NH 
groups of HCT occur at the area between 3100 and 3370 cm·l which correspond to 
the symmetric vibration of secondary N-H group, the NH2 symmetric vibration and 
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the symmetric vibration of the NH group of the primary and secondary 
sulphonamide. The strong peaks at 1150 and 1165 cm·l corresponds to the 
symmetric vibration of 502 whereas the peaks at 1295 and 1313 cm·l correspond to 
the asymmetric vibration of 502. The strong peak at 1596 cm·l assigned to the NH2 
bending vibration . Also, the strong peaks at 680 cm-l and 710 cm-l correspond to the 
CS stretching vibration. 
In the sprayed HCT the peaks corresponding to the NH group which are in the range 
3160 - 3500 cm-l wavenumbers became broader indicating the amorphous nature of 
the product. Furthermore, the second peak moved to lower wavenumbers than in 
crystalline material indicating that the hydrogen bonding between the HCT 
molecules are stronger than in the crystalline form whereas the peak of the amino 
group at 3360 cm-l , even though it is broader than in crystalline form it has been 
remained in the same position indicating that the certain amino group does not 
compete to the hydrogen bonding. Also, it is worth noticing that the peak at 3167 
cm-l looks to have shift to higher wavenumbers and unified with the peak at 3263 
cm-1 (Figure 3.22) . 
Furthermore, the peak which corresponds to the symmetric vibration of 502 group 
looks to be in the same position with the crystalline, even though it is difficult to 
elucidate it due to their broadness. 
Figure 3.22: Raman spectra of powder HCT and sprayed HCT. 
• HCT sprayed 
- HCT powder 
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When PVP is added to the formulation its characteristic peak appears, whose 
intensity increases as its concentration increases (Figure 3.23). The most 
characteristic peaks of PVP are the peak corresponding to the carbonyl group at 1662 
cm-
l 
and the carbonyl ring at 938 cm-l . The carbonyl group of PVP can interact via 
hydrogen bonding with the NH group of HCT. Focusing on the NH region of sprayed 
HCT and 2/1 = HCT/PVP mixture, it is observed that both the peaks corresponding to 
amino groups have been slightly shifted indicating hydrogen bonding between the 
PVP and HCT. However, the carbonyl group of PVP remains in the same position with 
the pure material. Finally, the peaks of symmetric and asymmetric SO stretching 
have been shift slightly to higher wavenumbers. 
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Figure 3.23: Raman spectra of sprayed HCT, and mixtures of HCT/PVP of various ratios with zoom on the 
NH area of sprayed HCT and 2/1 = HCT/PVP sprayed mixture. 
The spectra of HCT/PLGA in different ratios are illustrated in Figure 3.24. As in the 
case of PVP, when PLGA is added, its characteristic groups are appeared. The C=O 
group of PLGA can interact with NH group via hydrogen bonding, however there is no 
peak shift of neither the NH groups of HCT, nor the C=O group of PLGA which does 
not confirm any hydrogen bonding between the API and the polymer. Also, PLGA 
could interact with HCT via hydrogen bonding of its OH group with the SO groups of 
HCT. Nevertheless, the peaks corresponding to the SO group at 
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Figure 3.24 : Raman spectra of sprayed HCT, PLGA and mixture of HCT/PLGA = 30/70 with zoom in the 
area of NH group. 
In Figure 3.25 the Raman spectrum of the mixture of HCT with PLGA and Pluronic is 
shown. Due to its low concentration the pluronic's peak can not be detected in the 
spectra of the mixture. Pluronic can interact with the PLGA and HCT with hydrogen 
bonding of its hydroxyl group. However, this could not be confirmed as the carbonyl 
peak of PLGA remained at the same position in the mixtures. Also, the second peak 
of NH group of HCT looks to be slightly shifted indicating hydrogen bonding between 
the NH group of HCT and the CO group of PLGA (Figure 3.26a). Finally the peaks that 
correspond to the S02 group of HCT which can be associated with pluronic via 
hydrogen bonding remains in the same position with the sprayed HCT indicating that 
no interaction between HCT and pluronic took place (Figure 3.26b) . 
• Sprayed HCT 
. Sprayed mixture of HCT/PLGAlPluronic = 50145/5 
- Pluronic 
- PLGA 
.. , .. 
Figure 3.25: Rama n spectra of sprayed HCT, pluronic, PLGA and sprayed HCT/PLGA/Pluronic = 50/45/5 
mixture. 
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· Sprayed HCT 
• Sprayed HCTIPLGAlPturonrc 
• Sprayed H CT 
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Figure 3.26: Raman spectra of sprayed HCT and sprayed mixture of HCT/PlGA/Pluronic = 50/45/5 
mixture in the a) NH region and b) so region. 
3.5.5 Raman Mapping 
3.5.5.1 Felodipine 
Confocal Raman Microscopy has been applied to study the drug distribution and 
state within the micro-spots. The spectral peaks chosen to plot the map were the 
characteristic carbonyl group of felodipine at 1667cm-1 and the characteristic carbon 
ring breathing of PVP at 937cm-1. Figure 3.27a,Figure 3.28a, Figure 3.30a, Figure 3.31a 
show the Eigenvalues for each principal component. It is observed that the 
Eigenvalues are reduced dramatically after the first factor and it is almost zero after 
the third factor which indicates that the contribution of more than three factors is 
limited. Hence, the chemical map of the product has been created by using three 
principal components (PCs) for the mixtures of felodipine/PVP 2/1, 1/2 and 1/10 and 
two principal components for the mixtures 1/2 and 1/5. 
As it can be seen from the model spectra and the chemical maps (Figure 3.27,Figure 
3.28,Figure 3.29,Figure 3.30 and, b and c), the API and the polymer is evenly 
distributed as the characteristic peaks of felodipine and PVP coexist in the model 
spectra. The model spectra used to create the chemical maps were separated based 
on the intensity of the peaks. Therefore, the model spectra with the less intensity 
correspond to areas with a less concentration of material and are located at the edge 
due to the curvy shape of the droplet. 
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Figure 3.27: a) Eigenvalues plot versus PCs numbers of the Felodipine/PVP = 2/1 mixture b) 3 model 
spectra used to create the chemical map where the red, blue and green correspond to background, 
both background and sample respectively )optical microscope image of deposited product d) Chemical 
image of the mixture. 
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Figure 3.28: a) E i g e n v a l ~ ~ s s 'plot versus PCs numbers of the Felodipine/PVP = 1/1 mixture b) 2 model 
spectra used to create the chemical map, where the red and the green correspond to the sample and 
background respectively c)optical microscope image of deposited product d) Chemical image of the 
mixture. 
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Figure 3.29: a) Eigenvalues plot versus PCs numbers of the Felodipine/PVP = 1/2 mixture b) 3 model 
spectra used to create the chemical map, where the red, blue and green correspond to background, 
both background and sample respectively c)optical microscope image of deposited product d) Chemical 
image of the mixture. 
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Figure 3.30: a) Eigenvalues plot versus PCs numbers of the Felodipine/PVP = 1/5 mixture b)2 model 
spectra used to create the chemical map, where the red, and the yellow correspond to background, and 
the sample respectively c )optical microscope image of deposited product d) Chemical image of the 
mixture. 
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Figure 3.31 : a) Eigenvalues plot versus PCs numbers of the Felodipine/PVP = 1/10 mixture b) 3 model 
spectra used to create the chemical map, where the purple, yellow and blue correspond to background, 
both background and sample respectively c)optical microscope image of deposited product d) Chemical 
image of the mixture. 
3.5.5.2 Captopril 
Figure 3.32 shows the chemical image for the captopril PLGA formulation. The image 
has been separated into three components. The differences of the model spectra are 
negligible as all of them contain peaks of both the captopril and PLGA leading to the 
conclusion that the product is homogenous. The red and the blue spectra are 
separated based on their intensity whereas the green spectra correspond to areas 
with very little material or to out of focus areas. 
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Figure 3.32: Eigenvalues plot versus PCs numbers of the Cap/PLGA = 50/50 mixture b) 3 model spectra 
used to create the chemical map, where the green corresponds to background areas and the red and blue 
to captopril!PLGA mixture c)optical microscope image of deposited product d) Chemical image of the 
3.5.5.3 Hydrochlorothiazide 
As shown from the eigenvalue plot versus the PC numbers (Figure 3.33,Figure 
3.34a,Figure 3.35a and Figure 3.36a), PCA analysis suggests using 2 factors to create 
the chemical image of the sample except the 1/1 HCT/PVP sample. Like in the case of 
felodipine/PVP system, the model spectra, indicates that the product of all the ratios 
HCTjPVP is homogenous as all model spectra contain peaks of both HCT and PVP. 
Moreover the green spectra in all the cases correspond to areas with less quantity 
material. Moving to the centre of the droplets the deposited material increases and 
the model spectra became stronger. The yellow areas correspond to areas where 
both the green and the red spectrum contribute to the spectrum in this areas. 
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Figure 3.33: a) Eigenvalues plot versus PCs numbers of the HCT/PVP = 2/1 mixture b) 2 model spectra 
used to create the chemical map, where the green and red correspond to both background and sample 
respectively c)optical microscope image of deposited product d) Chemical image of the mixture. 
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Figure 3.34: Eigenvalues plot versus PCs numbers of the HCT/PVP = 1/1 mixture b) 2 model spectra used 
to create the chemical map, where the red corresponds to background areas and the blue and the 
green to the captopril/PLGA mixture c)optical microscope image of deposited product d) Chemical 
image of the mixture. 
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Figure 3.35: Eigenvalues plot versus PCs numbers of the Ha /PVP = 1/2 mixture b) 2 model spectra used 
to create the chemical map, c)optical microscope image of deposited product . The green corresponds 
to background and the red to HCT /PVP mixture d) Chemical image of the mixture. 
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Figure 3.36: a) Eigenvalues plot versus pes numbers of the Ha/pvp ;; 1/5 mixture b) 2 model spectra 
used to create the chemical map, c)optical microscope image of deposited product d) Chemical image of 
the mixture. 
In Figure 3.37a the Eigenvalues plot with the principal components for the HCT/PLGA 
30/70 is illustrated. From this plot, it is clear that the factors that can contribute to 
the obtained spectra are the first five. The chemical map Figure 3.37d has been 
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created by separating the spectra in to five principal components. Hence, the areas 
corresponding to yellow model spectrum are areas containing only HCT since the 
characteristics peaks of PLGA such as the carbonyl group at 1760cm-1 are missing in 
model spectra. The red, purple and blue area contain both HCT and PLGA as the 
model spectra corresponding to these contain the characteristic peaks of HCT and 
the characteristic peak of PLGA at 1760cm-1• However, they are not equally 
distributed as the ratio of these characteristic peaks of HCT and PLGA is not the same 
to all the model spectra. Hence, the blue areas where the ratio of the C=C of HCT to 
the carbonyl group of PLGA is the biggest, contains the higher concentration of HCT 
where the red and purple areas the lower concentration as the ratio is the smallest. 
Also, the optical microscope image combined with the chemical image shows that 
the polymers have been accumulated at the top of the sample, in contrast with the 
drug which is distributed in all the place. 
The chemical images of the mixtures of HCT and PLGA at ratios of 30/70 and 20/80 
are illustrated in Figure 3.37 andFigure 3.38. In the case of 30/70 HCT/PLGA the 
green spectrum corresponds to the background whereas the others correspond to 
the sprayed product. As these spectra, contains peaks of both the compounds such 
as the strong C=C peak of HCT at 1604 cm-1 and the carbonyl peak of PLGA at 1750 
cm-I , both the compounds are distributed to all the sample. 
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Figure 3.37: : a) Eigenvalues plot versus PCs numbers of the HCT/PLGA = 30/70 mixture b) 5 model 
spectra used to create the chemical map, where the green, yellow correspond to background and to 
HCT respectively whereas the red, blue and pu rple correspond to areas with mixture of HCT and PLGA in 
different concentrations c) optical microscope image of deposited product d) Chemical image of the 
mixture. 
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Figure 3.38: : a) Eigenvalues plot versus PCs numbers of the HCT/PLGA = 20/80 mixture b) 2 model 
spectra used to create the chemical map, c)optical microscope image of deposited product d) Chemical 
image of the mixture. 
72 
3. Production of individual sprayed formulations 
In the case of the mixture of HCTjPLGAjPluronic mixture the PCA analysis showed 
that four factors contribute to the spectra obtained (Figure 3.39a) . Hence, the chemical 
map of the spot has been separated in to four PCs. The purple and blue spectra 
contain peaks of both HCT and PLGA indicating the coexistence of the two 
compounds. The red spectrum corresponds to areas with HCT as only the peaks of 
API appeared. The green model spectra express areas which contain the less 
material. Unfortunately, Raman was not able to distinguish the pluronic's 
characteristic peak due to its low concentration and because most of the pluronic 
peaks are overlapped from those from PLGA and HCT. Finally, the optical microscope 
image combined with the chemical image shows that the API is evenly disturbed 
combared with the polymers. 
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Figure 3.39: a) Eigenvalues plot versus PCs numbers of the HCT/PLGA/Pluronic = 50/45/5 mixture b) 4 
model spectra used to create the chemical map. The green spectrum corresponds to background, the 
red spectrum corresponds to pure HCT and the pink and the blue spectra correspond to the mixture of 
HCT /PLGA c)optical microscope image of deposited product d) Chemical image of the mixture . 
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3.6 Discussion 
In this chapter, drug formulations of felodipine, captopril and hydrochlorothiazide 
with polymers have been prepared by using the inkjet printing method. A 
combination of micro and nano analytical methods has been implemented to study 
the physicochemical properties of these formulations. 
3.6.1 Felodipine 
In terms of the felodipine/PVP system AFM confirms that the product is 
homogenous, amorphous without phase separation at the drug-polymer ratios used. 
Also, the importance of the evaporation rate has been confirmed as it can affect the 
physical form of the final product. A slow evaporation rate can lead to crystallization, 
which can lead in turn to a dramatic change in therapeutic properties of the 
medicine through a reduced solubility. 
The homogeneity of the product was confirmed by LTA, where only one glass 
transition point was detected for the mixtures at the micrometre (SThM) and 
nanometre scale (NTA). However, it is worth noticing the differences between the 
measured TI and the theoretical values derived from the Gordon-Taylor equation. 
The reason for this is probably related to the fundamental principle of L TA. In 
general, at both the micro and nano-scale the thermomechanical contribution of the 
physical contact area of the tip is an important factor in the thermal response of the 
samples. Tsukruk et 01. investigated this mechanical contribution by measuring the 
probe heat dissipation which is dependent on the probe/surface contact area for a 
certain material. The results showed that at an increasing indentation depth, there is 
an increase in the observed temperature for a glass transition above its actual value 
[144]. This phenomenon has a smaller effect on the measurements of the SThM due 
to the larger size of the initial contact region [145]. It is important to note that these 
phenomena do not affect the observation of a single TI . 
ATR spectroscopy reveals the association of felodipine with PVP to be via hydrogen 
bonding consistent with previous publications. In comparison to the literature the 
current study reveals the association of the drug and the polymer with two kinds of 
bonds even at a 2/1 Felodipine!PVP. Previous studies of solid dispersion of felodipine 
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with the PVP showed that at the higher concentration of felodipine only one peak at 
the higher wavenumbers of the amino group appears indicating only weak hydrogen 
bonds are formed [132]. This may be due to the inkjet printing method, where the 
amount of product is much less than in bulk solid dispersion methods. Consequently, 
the solvent is evaporated more rapidly possibly leading to a more intimate 
interaction of the PVP and felodipine. Also, ATR revealed that the hydrogen bonding 
among the felodipine's molecules in the amorphous sprayed material are stronger 
than in crystalline powder as the peaks corresponding to the amino group move to 
lower wavenumbers. This has also been confirmed by previous work [121). 
Confocal Raman microscopy has been applied as an additional analytical method to 
confirm the homogeneity of the product. The chemical map of the samples were 
processed using direct classical least square (DCLS) based on the algorithms of the 
NGLabspec. In order to choose the number of factors that contribute to the plot of 
chemical mapping, the Eigenvalues of each principal component was analysed. The 
PC Eigenvalues decrease with the number of components and level off when the 
complete signal is taken into account. For the experiments in this thesis, they sharply 
decrease after the first PC. Based on this behavior, it can be concluded that it is quite 
likely that two components exists. Indeed, the results indicate that in most of the 
cases two PCs, one coming from the samples and the other from the background, are 
enough to characterize the samples which show that both the compounds are evenly 
distributed along the mixture. Karavas et 0/ by applying confocal Raman mapping to 
solid dispersions mixture of felodipine with PVP and using the ratio of carbonyl peak 
to carbon ring band suggested that at elevated concentrations of felodipine 
aggregations of API's molecules can be observed [128). However, in our case by using 
NTA, a technique which can offer a much higher spatial resolution than confocal 
Raman microscopy did not reveal such agglomerations as all the measurements 
taken along the sample were far away from the glass transition temperature of 
felodipine. 
3.6.2 Hydrochlorothiazide 
AFM of HCT/PVP confirms that the product is homogenous, amorphous without 
phase separation at the drug-polymer ratios used. In the formulations where PLGA 
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has been applied the product is amorphous and there is a phase separation between 
the API and the polymer. 
SThM also confirmed the homogeneity of the product, since only one glass transition 
point has been detected. As in the case of felodipine/PVP system the values from LTA 
are increased compared to the theoretical values from the Gordon - Taylor equation. 
The explanation from this phenomenon must be sought again in thermomechanical . 
issues that govern the method. At this point, it is worth to noticing that both the 
lines plotted from the experimental and theoretical data are approximately parallel. 
This is an indication of a constant offset factor. Also, the homogeneity of the product 
is confirmed by the histogram of the SThM values, where in all the samples except 
the HCT/PVP = 1/1 sample the values are effectively constant. In the case of 
HCT/PVP, the high distribution ofT, values can come from the uneven distribution of 
the HCT in the sample, where the lower T, values correspond to areas with highly 
HCT concentration. 
ATR has been implemented to identify possible interactions between the HCT and 
the polymers. HCT can interact with PVP via hydrogen bonding of its amino groups 
with the carbonyl group of PVP. The potential hydrogen donors of HCT are the two 
amino groups of the primary sulfonamides, one from the secondary sulfonamide and 
one from a secondary amino group. The assignment of the NH peaks has been done 
previously by Tajber et 01. [143]. In general, the best hydrogen bond donor will bond 
to the best hydrogen bond acceptor. Moreover, hydrogen bond donating abilities 
correlate with the acidities, as the more highly acidic group is a better donor among 
the similar functional groups. In the case of HCT, according to Adsmond et al. [146] 
the amido proton is more acidic than the proton in the amino group, due to the 
strong electronegative character of the SO group which is able to polarise the 
nitrogen atom positively which in turn facilitates the release of the proton. 
Consequently, the API will interact with PVP via the amido group and therefore the 
peaks corresponding to NH of the sulphonamides will be shifted. Consequently, from 
the Figure 3.16d the first and second peak in the crystalline HCT powder can be 
assigned to the to the primary and secondary sulphonamide N-H peak, as these two 
peaks were shifted to lower wavenumbers when PVP was added. Unfortunately, the 
ATR spectrum was not able to distinguish the other two amino groups. 
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Raman spectra are consistent with the ATR spectra as the amino peaks became 
broader in the sprayed material and are moved to lower wavenumbers. From Figure 
3.23 the peak of the amino group at 3360 cm·l of the powder has shifted slightly 
when PVP is added and hence it will correspond to the asymmetric bonded stretch of 
the amino group of the primary sulphonamide. The amino groups at 3267 cm· l 
moved to even lower wavenumbers and therefore corresponds to symmetric stretch 
of either the amino group of either the primary sulphonamide or to the secondary 
sulphonamide. Unfortunately, due to the broadness of the peaks, it is not clear 
whether the amino peak at 3168 cm·l has moved to a lower wavenumber (Figure 
3.22). However, Tajber et 01. by using FTIR suggested that this peak must correspond 
to the stretching vibration of the primary sulphonamide [143]. The stretching of the 
secondary amino group is covered at by the peak of the asymmetric NH2 stretch. 
Also, vibrational spectroscopy was applied to investigate any possible interaction 
between the HCT and the PLGA. HCT and PLGA both can act as donor and acceptor in 
a hydrogen bond, as the hydroxyl group of PLGA can bond with the SO group of HCT 
and also the carbonyl group can interact with the amino groups of HCT. However, 
considering the large polymeric chain of PLGA, where only the carbonyl group exists, 
whereas only one hydroxyl moiety is present for each polymeriC chain, PLGA can be 
expected to act as an acceptor rather than a donor. Nevertheless, neither ATR nor 
Raman confirmed any peak shift of the carbonyl peak of PLGA remains in the same 
position with the pure PLGA. However, ATR showed a peak shifting of SO of HCT to 
higher wavenumbers for both the ratios of HCT/PLGA which is in a lower position 
from the crystalline powder (Figure 3.17c). This can be justified by a possible 
disruption of the SO···HN hydrogen bond among the molecules of HCT and direct 
formation of CO···HN hydrogen bond between the HCT and PLGA. This event can 
increase the energy of SO groups moving the peak to higher wavenumbers. The 
reason why this chemical and energetic transformation is not reflected by a peak 
shift of NH groups of HCT could be due to the peak broadness and the loss of their 
intensity which makes the analysis difficult. Also, it is likely that a limited number of 
HCT's molecules took part to the hydrogen bonding with the polymer, which also can 
explain the phase separation between the two compounds which was observed from 
the AFM. 
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To plot the chemical map of HCT with the others polymers the Direct Classic Least 
Square (DCLS) method has been used based on algorithms from the NGLabspec 
software. All the results confirmed the AFM results. Like in the case of 
felodipine/PVP the Hence, the HCT/PVP mixture results in a homogenous product at 
all the ratios applied, where both the compounds were distributed evenly in the 
samples. HCT/PLGA results to a product where the API is homogenously distributed 
in the samples whereas the polymer is accumulated in a certain area of the sample. 
Eigenvalues, as they sharply decrease after the first PC, suggest it is quite likely that 
two components exist. Even though, that in the phase separated samples they can 
be at least 3 components, the drug, the polymer and mix of drug and polymer, there 
are no pure polymer areas. The main reason for the phase separation is the 
Marangoni effect. According to this affect the liquid and hence any solute dispersed 
on it is moved towards the edge of the droplet due to unbalanced surface tension 
forces. This surface tension gradient is caused by the solvent evaporation which 
cools the droplet non uniformly. The temperature at the liquid-air surface at the top 
centre of the droplet is the lowest due to a longer thermal conduction path to the 
substrate, and the surface tension is highest at this point. This produces an inward 
flow near the droplet surface, whose shear stress balances the Marangoni stress, i.e, 
the surface-tension gradient [147-148]. Another theory which has been developed by 
Witten's group takes into consideration the generic properties of the substrate-
solvent interaction, the presence of surface roughness or chemical heterogeneities 
that produce contact line pinning which causes the gathering of the solute to the 
edge [149]. A description of the phenomenon is illustrated in Figure 3.40. If the 
contact line is not pinned during the evaporation, the hashed region would be 
removed from the drop, the interface would evolve from the solid line to the dashed 
line and the contact line would be moved from A to B. In the case where the contact 
line is pinned then there must be a flow that replenishes the liquid that is removed 
from the edge. At this point, it is worth noticing that these two theories complement 
each other; the Maragoni effect exists always but its effect can be minimized by 
reducing the evaporation rate of the solvent, whereas the phenomena described by 
the latter theory can be minimized by using a highly hydrophobic substrate (as used 
here) as the contact line will not be pinned. Consequentlv, the Maragoni effect is 
likely to playa dominant role in the form of the deposited material in this work. One 
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of the reasons for this phenomenon may be the fact that hydrochlorothiazide is 
soluble in acetone but not soluble in DMSO, whereas PLGA is freely soluble in both 
the solvents. Specifically, it has been shown by the Schubert's group that the usage 
of a mixture of two solvents where one of them has a low vapour pressure can 
improve the quality of the droplet and make it more homogenous [150-151] . As the 
DMSO evaporates more slowly than acetone, the concentration of DMSO at the edge 
will gradually increase. This will cause a decrease in the local vapour pressure, and 
therefore a decrease in the rate of evaporation at the edge and the amount of liquid 
that is transported from the centre to the edge. The 'coffee ring' effect can also be 
avoided by the usage of a mixture of two solvents, one with low solubility and a high 
boiling point and one with a low boiling point and high solubility for the compounds. 
In this case the dissolving potential of the solvent gradually decreases during 
evaporation and the compounds precipitate before a ring is formed [150]. Hence, 
HCT as it is insoluble in the DMSO it precipitated before the ring formation whereas 
PLGA as it is soluble in both, it precipitated after the evaporation of DMSO where 
due to the capillary forces by the evaporation will move the polymer. At this point it 
is worth noticing that in the case of felodipinejPVP mixture, any coffee ring 
formation was avoided as both compounds are soluble in ethanol and DMSO and 
also because of the hydrophobic which. made the droplet not to e pinned on the 
substrate. 
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Figure 3.40: Schematic diagram of the droplet evaporation. When the contact line is not pinned, (top 
picture) uniform evaporation removes the hashed layer, the interface moves from the solid line to the 
dashed line, and the contact line will move from A to B. However, if the contact line is pinned (bottom 
image) then the motion from A to B must be prevented by an outflow to replen ish the liquid removed 
from the edge. 
3.6.3 Captopril 
AFM reveals phase separation between the captopril and PLGA. Captopril appears as 
small dots which disappear after the sample is exposed to water. 
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ATR has been applied to investigate whether there is any conformational changes 
during the spraying of captopril and also if there is any possible interaction between 
the API and the polymer. To begin with, as shown in Figure 3.41 captopril like other 
proline containing peptides normally has an equilibrium conformation between cis 
and trans isomers. 
-• 
Figure 3.41: trans and cis (right) isomerization of captopril (152J . 
Furthermore, the trans:cis ratio at room temperature is 6:1 in aqueous solution, but 
the active form of captopril is the trans isomer when bound to the enzyme. However, 
this conformation is pH dependent. Around neutrality there is a significant amount of 
cis- isomer and so binding of cis isomer to the enzyme cannot be excluded a priori 
[153] . Therefore, the cis-trans interconversion of captopril is very important in 
pharmaceuticals and a number of studies have focused on its conformational 
analysis [154-156] . Rabenstein et of. found that the trans isomers of captopril in the 
solution were constructed by intramolecular hydrogen bonding of the amide group 
and the carboxylic acid hydrogen [155] . Consequently, in the trans isomer the 
intermolecular hydrogen bonding should be reduced due to the formation of the 
aforementioned intramolecular hydrogen bonding. As a result, the c=o stretching 
mode of carboxylic acid group and of amide group will shift to higher and lower 
frequencies respectively. The ATR results indicate that the sprayed drug is in cis form 
as the peak of carbonyl group of the carboxylic acid was moved to lower 
wavenumbers . Unfortunately, the peak corresponding to the c=o group of the amide 
is not clear enough in the crystalline material to have a clear conclusion of the 
chemistry of the sprayed captopril. However the double peak of the carbonyl group 
of the amide group indicates a coexistence of the cis and trans form. 
Raman analysis confirmed the ATR results as it is clear that the c=o group of 
carboxylic moved to lower wavenumbers, whereas the C=O group of amide moved 
to higher wavenumbers, indicating the formation of the cis-isomer. Nevertheless, 
Raman did not show any co-existence of the two isomeric form of captopril which is 
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probably due to the broadness of the peak caused by the amorphous nature of the 
product. 
When PLGA was added to the solution the (=0 peak of the carboxylic group of 
captopril was masked by the (=0 group of PLGA both in ATR and Raman spectrum. 
From the amide peak of captopril, ATR showed the coexistence of the two isomeric 
forms of captopril. Moreover, the Raman spectrum of the sprayed captopril and the 
captopril in the mixture (ap/PLGA are matching each other regarding the peaks of 
captopril, which confirms that captopril maintains the same chemical state. 
Another interesting point is the absence of the SH vibration peak in the ATR. This 
peak should be detected at 2500 - 2600 cm'l wavenumbers. Its absence could lead 
to the erroneous conclusion of the formation of disulfide, since captopril in aqueous 
solution can form disulfide (Figure 3.42) . 
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Figure 3.42: Structure of captopril disulphide. 
However, the fact that the peak in question was not detected even in the powder, 
and that the Raman shows the SH vibration leads to the conclusion that the only 
forms of captopril in the solution are the cis and trans isomers. 
An additional under investigation issue of the captopril/PLGA system is any possible 
interaction of the compounds by means of hydrogen bonding. (aptopril can act 
either as a donor via the SH and carboxylate groups or as an acceptor via its two 
carbonyl groups. PLGA, as was mentioned earlier, can act as an acceptor through its 
carbonyl groups and as a donor through the OH group. ATR did not confirm any 
hydrogen bonding between the (=0 group of PLGA and the SH group of captopril 
since the (=0 peak remain at the same position with the sprayed material. 
Moreover, the SH peak in the Raman spectrum remains in the same position as well. 
For the same reason hydrogen bonding via the (=0 groups of captopril and the OH 
group of PLGA was not confirmed as the amide peak remains in the same position 
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whereas the carboxylic peak was not able to be investigated as it is covered by the 
stronger peak of PLGA. 
Raman microscopy also showed that, the compounds are evenly distributed. This 
does not agree with the findings from the AFM where it showed that captopril is 
phase separated from PLGA. The reason why the phase separation is not detected by 
the Raman microscopy is because of its resolution limitation which is around l ~ m m
equal to the size of the beam. In terms of the distribution of the API and the polymer 
in the product, confocal Raman microscopy showed that the API tends to move to 
the centre, leaving the polymer at the edge. This can be justified by the fact that the 
polymer is deposited first and as the droplet was shrinking during the evaporation 
due to the hydrophobic surface the remaining compounds are deposited in the 
centre. 
3.7 Conclusions 
In this chapter three different APls along with certain excipients were successfully 
printed using a piezoelectric driven dispenser. Felodipine and PVP produced a 
homogenous product as AFM and LTA confirmed. The interactions of felodipine with 
the polymer by means of hydrogen bond were also established by ATR - FTIR. Finally, 
Confocal Raman microscopy showed that both felodipine and PVP are distributed 
along the surface. 
The micro-printing of captopril/PLGA solution results in a phase separated product. 
Also, it appears that the deposited captopril was converted from trans to cis form as 
shown by Raman and ATR. Finally, vibrational spectroscopy did not prove any 
interaction between captopril and PLGA. 
Hydrochlorothiazide/PVP results are similar with the felodipine/PVP system. More 
specifically, it produced a homogenous product according to the AFM, LTA and 
Confocal Raman mapping analysis. Interaction between the two compounds has 
been also confirmed by ATR. 
In contrast, in the HCT/PLGA system the two compounds are phase separated 
according to AFM. Finally, ATR showed that there can be hydrogen bonding between 
the NH group of HCT and the CO group of PLGA. 
82 
4. Release the API from individual printed spots 
4. Investigation of the release of 
felodipine from individual 
printed felodipine/PVP spots 
4.1 Introduction 
In this chapter, the investigation of inkjet printing as a method to prepare medicines 
is extended. In every drug formulation, one of the most important aspects is to 
investigate how the drug is released. Typically, an in vitro drug release profile from 
the formulation is determined using standard dissolution apparatus type I or II 
following the USP standards, with the drug concentration in solution being 
determined by UV spectroscopy or HPLC. Specifically, the medicine is exposed to an 
appropriate solvent at 36°C and samples are taken at regular time paints. The UV 
absorbance of the characteristic wavelength of the API of interest is measured and 
subsequently, the release profile of the API is plotted, as the concentration of the 
compound is proportional to the UV absorbance according to the Beer - Lambert law 
[157-159J. 
However, here, the low quantity of the deposited material does not allow the use of 
UV spectroscopy for the dissolution experiments. Therefore, confocal Raman 
microscopy was applied to investigate the dissolution properties of felodipine/PVP 
mixture, since the intenSity of the bands of Raman spectrum are proportional to the 
concentration of the chemical group corresponding to the chemical group. 
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4.1.1 Potential incorporation of conventional control released 
techniques to inkjet printing 
A common approach to increase the solubility of a drug substance is to reduce its 
particle size and thus increase the surface area in contact with a solvent for a given 
mass of material. Inkjet printing can provide this opportunity by spraying different 
quantities of material, producing a microarray, where each sprayed product will have 
different dissolution properties depending on the drug loading [160]. Also, the 
spraying of a relatively insoluble API with a soluble excipient can provide a solid 
dispersion product with improved dissolution properties. Application of this concept 
is demonstrated in this chapter where the poorly soluble API, felodipine is 
incorporated with soluble PVP to produce a solid dispersion mixture. 
Moreover, there are various concepts which can help to prepare solid drug dosage 
forms by modifying the release profile of the API. For example, API could be 
incorporated with a slowly biodegradable polymer which can serve as a slow-release 
polymer matrix. This concept has been applied by Xie et 01. where they prepared 
biodegradable films with controllable thickness for control sustained release 
applications of paclitaxel encapsulated in poly(lactic-co-glycolic acid) PLGA (161]. This 
concept is also discussed in chapter 6 where the release profile of 
hydrochlorothiazide and captopril was modified by co-spraying with PLGA. 
Another potential way to modify the release profile of the drug is to spray a suitable 
coating onto the API. Coatings have been used to delay drug release and to protect 
the drug from undesirable physiochemical conditions in parts of body such as gastric 
environment, releasing the API at a desired location [162]. For instance ethyl 
cellulose in combination with hydrophilic polymers such as the co-polymer PVA-PEG 
[163] or HPM [164] can modify the release and protect the API from being dissolved 
until it reaches the desired therapeutic area. 
4.1.2 Quantitative Raman Analysis 
Raman spectroscopy has been proved to be an excellent tool not only as a qualitative 
method of analysis but also for quantitative determination of compounds in a 
mixture [165-166]. Several quantitative Raman studies have been applied to 
mixtures of liquids [167-169]. However, the use of Raman to quantify compounds in 
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solids mixtures is a complicated issue because the Raman bands depend on external 
factors such as sample alignment and homogeneity. Therefore, to gain quantitative 
information the ratio of two bands is used, unless an internal standard can be found 
[165] such as a solvent which does not interfere with the sample. In more complex 
systems, quantitative data are processed using chemometrics techniques based on 
multiple linear regression or principal component regression which depend on band 
intensity comparison [165-166]. 
In theory, the intensity of a Raman peak is dependent on the polarizability of the 
electrons in the molecules which leads to a complex expression of the intensity 
[170]. A simple formula for the intensity which is analogous to the Beer - Lambert 
law and it is suitable for analytical purposes can be expressed as; 
I = KVCo (4.1) 
Where 10 is the intensity of the exciting radiation, V is the volume of sample 
illuminated by the source and viewed by the spectrometer, C is the concentration of 
the sample and K is the constant for each band. 
In this chapter, the proportional association of the intensity of characteristic bands of 
felodipine and PVP has been used to quantify the amount of the compounds in the 
mixture. 
4.2 Alms - Objectives 
This chapter aims to study the dissolution properties of a single material spot 
consisting of various ratios of felodipine and PVP. Due to the low quantity of the 
deposited materials, the release of the API has been investigated by using the 
intensity of the characteristics peaks of PVP and felodipine in Raman spectra of the 
felodipine/PVP mixtures. 
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4.3 Materials - Methods 
4.3.1 Materials 
Felodipine was supplied by AstraZeneca (Charnwood, Leics, UK), PVP k30 and DMSO 
99% anhydrous were purchased from Sigma-Aldrich. Flutec fluid was purchased by 
F2 chemicals (Lancashire, UK). 
4.3.2 Methods 
4.3.3 Preparation of solutions 
Solutions of felodipine and PVP were prepared by dissolving them into a mixture of 
ethanol and DMSO (95/5). Felodipine is soluble in ethanol. DMSO was used to 
increase the boiling point of the solution to reduce chances of the dispenser clogging 
due to evaporation of the solvent. The ratios of felodipine to polymer were lIla, 
lIS, 1/2 (wlw). 200 droplets of each solution were sprayed onto flutec coated glass 
coverslips. The samples were dissolved in 2ml of deionised water and dried in the 
vacuum. AFM and confocal Raman studies were executed before and after 
dissolution. 
4.3.4 Atomic Force Microscopy 
AFM analysis was performed in air by tapping mode using a Dimension 3000 
(Nanoscope ilia controller, Vee co, CA). Tap300 cantilevers were used (Budget 
Sensors, Sofia, Bulgaria). The images were subsequent analysed using SPIP software 
4.3.5 Confocal Raman 
Confocal Raman studies were performed on the dried deposits from the 200 droplets 
using a Jobin-Yvon/Horiba micro-Raman spectrometer, by means of a red laser with 
a 632nm wavelength and a 600 l/nm grating. The spectrometer is equipped with an 
Olvmpus microscope BX41. 
The chemical images were obtained using a 100llm slit width, a loox microscope 
objective and 1 sec exposure time. Each spectrum was the mean of two 
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measurements. The sample profiling was performed at step increments of 5 ~ m m in x-
and y- directions. 
To investigate the dissolution profile of felodipine from the spot formulations, these 
were exposed to 2 ml deionised water media for a range of time periods, dried and 
the Raman spectra acquired from several points of the sample (Figure 4.1). The mean 
spectrum of these was applied for the analysis. The mean spectrum was created by 
merging individual spectra shifting the data to make the same average intensity 
levels on the overlapping sections. The intensity of each peak is proportional to the 
concentration of the chemical group that corresponds to that peak. In Figure 4.2 the 
change of the intensity of the carbonyl and carbon ring of PVP as a function of 
felodipine and PVP's concentration is represented . These figures show that as the 
concentration of felodipine and PVP increases, the intensity of the carbonyl peak and 
the carbon peak increases in proportion. Consequently, any alteration of the peaks 
of the carbonyl group of felodipine and of the Coring's peak of PVP can be used to 
quantify the proportional change of the corresponded compound. To achieve this, a 
calibration curve of the concentration of the felodipine as a function of the ratio of 
the carbonyl peak to carbon ring peak was produced (Figure 4.3a). Based on this 
calibration, the change of the drug concentration in the formulation during the 
dissolution of the samples was determined. 
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Figure 4.1: A representative optical microscope image magnified x100 of 1/5 felodipine with the points 
highlighted where the spectrum obtained. For the dissolution studies the mean spectrum of these were 
used. 
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Figure 4.2: a) Change in the intensity of the carbon ring as a function of the concentration PVP in the 
felodipine/PVP mixture, b) Change in the intensity of the carbonyl ring as a function of the 
concentration felodipine in the felodipine/PVP mixture. 
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Figure 4.3: Change in the ratio of carbonyl peak to the carbonyl ring as a function of the API/PVP ratio. 
4.4 Results 
4.4.1 Atomic Force Microscopy 
4.4.1.1 Felodipine/PVP = 1/10 
Figure 4.4 shows a topographic and phase AFM image of the 1/10 felodipine/PVP 
mixture. Before the dissolution of the mixture small holes were typically observed 
due to the drying of the mixture onto the substrate. After dissolution for 3sec, larger 
holes could be observed whereas after 5 sec these holes had become interconnected 
due to the loss of more material. After 10 sec dissolution time the product was 
topographically homogenous as more material was lost extinguishing all the features 
leaving small of little holes on the sample. 
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Figure 4.4: Topographic [152) and phase (right) AFM images of 1/10 felodipine/PVP mixture a) before 
the dissolution in water and after the dissolution for b) 3see, e) 5see and d) 10see. 
4.4.1.2 Fe/odipine/PVP = 1/5 
From topographic AFM images 1/5 felodipine/PVP mixture (Figure 4.5), it is clear that 
as the dissolution time increases, more material was removed as expected due to the 
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dissolution of PVP. Also, AFM phase data did not illustrate any phase separation of 
the compounds or crystallization. 
Figure 4.5 : Topographic [152] and phase (right) AFM images of 1/5 felodipine/PVP mixture a) before the 
dissolution in water and after the dissolution for b) 3sec, c) 10sec. 
4.4.1.3 Felodipine/PVP = 1/2 
Figure 4.6 illustrates topographic and phase AFM images of a 1/2 felodipine/PVP 
mixture. The results are similar to the previous two mixtures. Hence, the dissolution 
results in a loss of material, however the product remains homogenous without any 
sign of phase separation or crystallization . 
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Figure 4.6: Topographic [152] and phase (right) AFM images of 1/5 felodipine/PVP mixture a) before the 
dissolution in water and after the dissolution for b) 3sec, c) 10sec and d) 15sec, e) 20see. 
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4.4.2 Confocal Raman mapping 
The most appropriate peaks of the spectra to investigate the sample during the 
dissolution were the carbonyl peak of felodipine at 1660cm·l and the peak 
corresponding to the carbonyl ring at 937 cm·l . 
4.4.2.1 Fe/odipine/PVP = 1/10 
Raman mapping images of the felodipine/PVP mixtures have been separated into 
four components. In the case of 1/10 felodipine/PVP mixture the model spectra for 
all the dissolution times contains the peaks of felodipine and PVP indicating that 
there is no phase separation between the components at the scale of observation of 
the Raman (approx. 0.5 ~ l m ) . . The model spectra have been created based on the 
intensity of the spectra's peaks. 
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Figure 4.7: Raman chemical images of 1/10 felodipine/PVP mixture a) before dissolution, and after b) 
3sec, c) Ssec, exposure to dissolution media. 
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4.4.2.2 Fe/odipine/PVP = 1/5 
Similar data are observed for the 1/5 felodipine/PVP mixtures as for the 1/10 
felodipine/PVP mixture (Figure 4.8). The product remains homogenous at all time 
points. Also, it is worth noticing that in the sample which is dissolved for 5sec, there 
are areas assigned in red colour which indicates a higher concentration of felodipine 
as the ratio of the carbonyl peak to the carbon ring peak of PVP is larger in the 
spectrum corresponding to these areas (Figure 4.8c). 
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Figure 4.8: : Raman chemical images of 1/5 felodipine/PVP mixture a) before the dissolution, and after 
b) 3sec, c) 5sec, d) lOsec 
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4.4.2.3 Feiodipine/PVP = 1/2 
In the case of the 1/2 felodipine/PVP mixture the product continues to remain 
homogenous. The spectra at all the dissolution time points are qualitatively similar 
indicating that the sample remains homogenous during dissolution. 
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Figure 4.9: Raman chemical images of 1/2 felodipine/PVP mixture a) before the dissolution, and after b) 
3sec, c) lOsec, d) 30sec, e) 45 sec .. 
94 
4. Release the API from individual printed spots 
4.4.3 Dissolution profiles 
Figure 4.10 shows the mean Raman spectra at the different dissolution time points 
for each of the felodipine-PVP ratios. It is clear that in the case of 1/10 
felodipine/PVP mixture the intensity of all the peaks are reduced, indicating that 
both the felodipine and the PVP are being released into solution (Figure 4.10a). In 
the case of l/S and 1/2 felodiplne/PVP mixtures the peaks of PVP are reduced, 
whereas the peaks corresponding to felodipine increase their intensity (Figure 4.10b, 
c). 
The dissolution profiles of felodipine from the deposited spots, i.e. the mole fraction 
of API versus dissolution time are illustrated in Figure 4.11 for different drug!PVP 
ratios. It is appears from this that the PVP is preferentially removed from the spot as 
the dissolution experiment progresses resulting in a relative increase of API. For ease 
of comparison, these data are recast as the change in the amount of felodipine 
during the dissolution relative to the initial amount in Figure 4.12b. Here it is clear 
that the loading of the drug in the deposited spots plavs an important role In the 
dissolution properties of the formulation with the dissolution rate reduced at higher 
loadings. 
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Figure 4.10: Mean Raman spectra of a) 1/10 felodipine/PVP mixture, b) 1/5 felodipine/PVP mixture and 
c) 1/2 felodipine/PVP mixtures 
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felodipine/PVP, c) dissolution profiles of felodipine/PVP mixture. 
4.5 Discussion 
From the phase images of AFM and from Confocal Raman mapping showed that all 
the mixtures are homogenous without phase separation and remain so during the 
dissolution conditions employed. At this point, it is worth noticing that the mixture 
remains homogenous during the dissolution probably due to the strong interactions 
between the drug and the polymer, which inhibits mobility of the drug and hence its 
potential to phase separate and crystallize. Phase separation between felodipine and 
PVP is a common phenomenon in bulk formulations, for example due to the 
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influence of humidity. Marcac et 01. showed that storing films of felodipine/PVP 
mixture in elevated moisture, leads to crystallization and subsequently phase 
separation [171J. However, this process was relatively slow, beginning after the first 
hour with a phase separation of the compounds and crystallization of felodipine after 
four hours. In these cases water is believed to plasticize the polymer within the 
dispersion leading to an increased mobility of the drug. In our case after the 
dissolution of the samples for some seconds, they were dried in vacuum and stored 
in a desiccator to avoid such humidity effects. 
The dissolution studies showed that the drug dissolution profile is highly dependent 
on the initial drug loading. At higher loadings no detectable amount of drug was 
released within the timescales studied. Also, confocal Raman microscopy revealed 
that in simulated dissolution studies, PVP is dissolved much more rapidly than 
felodipine for all the drug loadings. In literature, PVP has been extensively used to 
increase the dissolution rate of various insoluble compounds [172-174J. Specifically, 
it has been shown that as the proportion of PVP increased, felodipine dissolution 
rates increased and reached a plateau at a ratio of 1:10 [125, 128-129J. Moreover, 
Kin et 01. showed that during the dissolution process of PVP solid dispersions, the 
concentration of felodipine in the medium reached around eight times the solubility 
of crystalline felodipine and then slightly decreased with time [125J which is due to 
suppression of felodipine's recrystallization by the PVP[124J, which is known as an 
inhibitor of drug recrystallization in general due to the hydrogen bonding between 
the drug and the polymer [175J. 
Moreover, it has been proved that the main factor which affects the release profile 
of felodipine is the intensity of this hydrogen bonding with the polymer matrix [126]. 
These interactions can promote the dispersion of the drug that is surrounded, in 
molecular level, by polymer chains, and restrict its ability to form crystal lattices with 
its neighbouring drug molecules [124, 126J. Also, Karavas et 01. showed that a 
maximum interaction is achieved when the polymer's concentration is more than 
75% (w/w), whereas below 60% (w/w) there is a dramatic decrease. Furthermore, it 
has been confirmed that the required molar ratio between felodipine and PVP in 
order for the interaction to be fully developed is 1:40 [176J. In our case both 
compounds are dissolved in ethanol and DMSO. As the solvents are evaporated, the 
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less soluble compound, felodipine in this case [177-178], will be precipitated first. 
Consequently, the higher concentration of felodipine is used the more material 
which is not associated with the PVP can exist. 
Here, preliminary studies showed that when the concentration of the sprayed 
solution decreased from 20mg/ml to lOmg/ml In the 1/2 felodiplne/PVP mixture, 
almost all the API was dissolved in lOsecs. Figure 4.13 shows an optical microscope 
image of the remaining product after being dissolved in delonised water for lOsec 
and the mOdel spectra used to create the mapping. As can be seen, the model 
spectra are the spectra of pure PVP Indicating that all the API has dissolved In 
contrast with the 20mg/ml solution where API was remained on the surface. This 
phenomenon can be justified if we note that the deposited material is on a 
hydrophobic coated surface. This makes the product more compact on the substrate. 
During drying and loss of solvent the API molecules will become more crowded 
promoting molecular interactions. 
There are also other possible technical reasons why in the present study that the 
drug is not to dissolved when a higher concentration of API is used. First and 
foremost, the intensity of the Raman peak can be affected by sample topography 
after the dissolution and also by any conformational change of any chemical group. It 
is well documented that the intensity of the Raman peak depends on the orientation 
of chemical groups [179-181]. For instance, when the polar orientation of a specific 
chemical group is parallel to the incident beam the intensity of the Raman band is at 
a maximum. Consequently, it is difficult to predict what effect the dissolution of the 
sample in water would have. Even though, AFM showed that the samples are 
relatively flat, on the mlcroscale the shape of the under Investigation product was 
topographically completely different for the dried droplets before and after 
dissolution. 
Due to the aforementioned technical issues related to the intensity of the band, the 
concentration of the API was measured by both the intensity of the carbonyl peak 
and by the ratio of the carbonyl peak to the ratio of carbon ring of PVP. From the 
Figure 4.14, it is clear that there Is a linear relationship between these two 
approaches, indicating that they are consistent. 
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Figure 4.13 : optical microscope, chemical image and the model spectra used to plot the chemical map. 
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Figure 4.14: Correlation of the API 's release, measured by the intensity of carbon ring and the ratio of 
API/PVP with the API 's release measure by the intensity of carbon ring. 
4.6 Conclusions 
In this chapter, t he re lease of the AP I from a single spot was investigated using 
confocal Raman microscopy. This method was used as a substitute for the 
conventional uv techniques. The results showed that the dissolution of felodipine is 
highly dependent on the concentration of API to the formulation since in the 
formulation where the API was less concentrated, the drug was almost all released, 
whereas in the other formulations with higher drug loading the drug remained on 
the substrate . Even though, the reason for this is unclear, it can be speculated that 
the increased concentration of API in the sprayed solution with the hydrophobic 
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substrate can bring felodipines' molecules closer inducing hydrogen bonding among 
them which can not break apart during the dissolution. Moreover, preliminary 
studies showed that the dissolution of the drug is also dependent on the 
concentration of the sprayed solution since by reducing the concentration to half, 
even the drug at 1/2 felodipine/PVP mixture was dissolved It was interesting to 
notice also that during the dissolution, the remaining PVP still was in homogenous 
mixture. 
The dissolution results presented in this chapter are proof that inkjet printing can be 
a viable method to produce solid dispersion formulation with tailored release and for 
instant consumption. 
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5. Production of an array of a 
single API 
S.l Introduction 
Previous chapters proved the feasibility of producing drug formulations of various 
APls and eXcipients in dried deposits of spayed micro-droplets. The next step was to 
scale-up the production process and prepare a dosage form with therapeutic 
capabilities through the production of arrays of dried droplets. Microarray printing 
technology has emerged as a key tool for high throughput screening of chemical 
compounds. 
One of the basic challenges and obstacle that had to be overcome for the 
preparation of the drug dosage forms based on inkjet printing was the low quantity 
of sprayed material in each droplet that had to be produced and analysed. To reach 
a therapeutic dose the sprayed solutions should be highly concentrated but this 
Increases the viscosity of the solution. In particular, solutions of high concentration 
of a polymer can be highly viscous. The piezodispenser used in these experiments 
can spray solutions up to a viscosity of Scp at the most and any increase in 
concentration of the solution should be used with caution. 
To avoid an undesirable increase in the concentration of the sprayed solutions, 
multiple droplets can be deposited on each spot. However, as we have seen in 
chapter 3, the deposition of multiple droplets can cause crystallization of product 
due to the slower solvent evaporation. 
In addition consideration should be given to possible blockage of the dispenser due 
to compound precipitation as described in chapter 3. To avoid this, the dispenser 
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was coated externally and internally with a hydrophobic material. Even though that 
it is not clear yet the effect that it had, there was no blockage of the dispenser. 
5.2 Time of flight ion mass spectroscopy (Tof-Sims) 
To show the reproducibility of the product produced by the microarray printer 
regarding the distribution of the API, Tof-Simns was applied . 
In Tof-Sims a beam of primary ions which is accelerated to a surface causes a series 
of collisions that eventually lead to the emission of a variety of species from the 
surface, including electrons, photons, neutral species and positively and negatively 
charged secondary ions. This is called the sputtering effect. Secondary ion mass 
spectrometry (SIMS) uses this effect to obtain information about the composition of 
the surface by analysing the fragments sputtered from the surface with a mass 
spectrometer. In static SIMS, the ion dose of the primary beam is kept low « 1013 
ions cm-2 ) in order to minimize the damage to the surface, whereas the higher dose 
of the ion beam used in dynamic SIMS causes erosion of the surface. 
In (ToF-SIMS), sputtered ions of one polarity are accelerated to a given potential. 
Before reaching the detector the fragments drift through a field-free path. Since all 
ions have the same kinetic energy at the beginning of the path, the time it takes 
them to travel a -xed distance only depends on their mass. Lighter ions reach the 
detector earlier than heavier fragments and can therefore be separated from each 
other. The main advantage of this method is that all ions of a given charge can be 
analysed at the same time [182]. 
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Figure 5.1: Particle beam interaction using ToF-SIMS. Incident particles bombard the surface liberating 
single ions (+/-) and molecular compounds. 
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5.3 Alms - Objective 
The aim in this chapter was to produce a viable dosage form (in terms of dosage) of 
felodipine mixed with PVP. Microarrays of felodipine/PVP were produced and 
characterised using AFM, SThM, confocal Raman microscopy and Tof-SIMS 
Dissolution studies of the formulation were utilised HPLC. 
5.4 Materials - Methods 
5.4.1 Materials 
Felodipine was supplied by AstraZeneca (Charnwood, Leics., UK). Polyvinyl 
pyrollidone (PVP) k30, poly(lactic-co-glycolic acid) (85:15) and DMSO 99% anhydrous 
were purchased from Sigma-Aldrich. Flutec fluid was purchased by F2 chemicals 
(Lancashire, UK). FASSIF powder was purchased by Phares (Basel, Switzerland). 
5.4.2 Methods 
5.4.2.1. Preptlratlon 0/ FASSIFsolution 
FASSIFphosphate buffer was prepared by dissolving 0.42 gr of NaOH, 3.9S4gr 
NaH2P04·H20 and 6.186gr NaCI In deionlsed water. The pH of the buffer was adjusted 
to 6.5 using NaOH. Subsequently, 2.24gr of Phares SIF Powder were dissolved in the 
buffer. 
5.4.2.2 Preptlf'tlt/on 0/ substrates 
Glass slides were coated by f1utec fluid using dip-coating method. 
5.4.2.3 Preptlratlon and spray 0/ solutions 
Felodipine and PVP were dissolved to acetone ethanol and DMSO (80/15/5). Ethanol 
was used to dissolve the PVP. Acetone was used because it was found that it sprayed 
easier than ethanol. Also, acetone increases the evaporation rate of the solution 
which can inhibit the formation of crystals. DMSO has been used to decrease the 
evaporation rate avoiding clogging of the piezo dispenser. 
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Polymer microarrays were formed using an ink-jet printer (i) (SciflexarrayerSS, 
Scienion). 10 mls of wash solution (Acetone) was flushed through the system at 60 
ill/S. Nozzle was then connected to the system and flushed with a further 2 mls of 
acetone at 10 ill/S. The nozzle used was a 90 ilm hydrophobic nozzle. Printing 
conditions were 15QC base temperature, 22QC air temperature, 34% humidity, 509 Hz 
frequency, 164 V pulse and 64 ils pulse width . The number of spots 16x49 where 300 
droplets deposited on each. 
c) 
Figure 5.2: photrographic images of a) the spray of solution from the dispenser, b) the production of 
microarray and c) representative microarray of the sprayed felodipine/PVP mixture. 
5.4.2.4 Atomic Force Microscopy 
AFM analysis was performed in tapping mode using a Dimension 3000 (Nanoscope 
Ilia controller, Vee co, CAl . Tap300 cantilevers were used (Budget sensors tapping in 
the air). SPIP software (Image metrology) was used to analyse the images. 
5.4.2.5 Scanning Thermal Microscopy 
SThM analysis was performed using an Explorer AFM system (Vee co, Santa Barbara, 
CAl with a Wollaston wire micro-thermal tip (Veeco) . Local thermal analysis was 
performed with a temperature rate of SOC/sec. The instrument was calibrated using 
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measurements on poly( l1l-caprolactone) (PCl) (Tm = 55°C), polyethylene (PE) (Tm = 
116°C) and polyethylenetelephalate PET (Tm = 238°C) . 
5.4.2.6 Confocal Raman 
Confocal Raman studies were performed on single spots using a Jobin-Yvon/Horiba 
micro-Raman spectrometer, by means of red laser with 632nm wavelength and 600 
l/nm grating. The spectrometer is equipped with an Olympus microscope BX41. 
Confocal Raman mapping has been applied to Felodipine/PVP mixture. The sample 
profiling at step increment were performed on 511m in x- and y- directions with 0.7 
sec exposure time. The data analysis was carried out in the NGlabSpec software. 
After acquisition PCA was carried out using routines from the software. 
5.4.2.7 Tof-Sims 
ToF-SIMS analysis was performed using an ION-TOF IV (GmbH, MOnster, Germany) 
instrument. To obtain spectra from eachpolymer spot secondary ions were sampled 
from a 100 x 100 11m area on each spot. Images and spectra were obtained using a 
Ga+ primary ion beam, operated at 25 kVenergy. 
5.4.2.8 Dissolution study of the micro array 
The dissolution rate of felodipine/PVP microarray printing has been measured using 
a beaker shaken with a shaking stage. Each sample was placed in FASSIFsolution in a 
concentration of 0.056 mg/ml. At predetermined time intervals, samples of Iml were 
withdrawn from the dissolution medium, filtered through 0.211m PTFE filter and 
assayed using the HPlC method for the drug. The calibration curve was constructed 
by dissolving felodipine in methanol in known concentrations. 
Figure 5.3: photographic image ofthe dissolution experiment. 
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5.4.2.9 HPLC analysis 
The chromatographic system was an HP agilet 1050. It consisted of a C8 gemini 
analytical column (100mm x 4.6mm). The mobile phase consisted of methanol and 
0.05M phosphate buffer (pH 3.5) (75/25 v/v) . The autosampler was set up to make 
20111 injections, every 7mins. The flow rate of the mobile phase was Iml/min and the 
detection was at 228nm at 40°C. The calibration curve was constructed by dissolving 
felodipine in methanol in known concentrations. 
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Figure 5.4: cal ibration curve of felodipine. 
5.5 Results 
5.5.1 Atomic Force Microscopy 
Figure 55 shows AFM images of the sprayed product produced by the microarray 
printing device. From these images, the products in all the cases appear homogenous 
and there is no sign of crystallisation. The holes that appear on the surface in all the 
cases are proposed to be due to the dehydration of the sample during the 
evaporation of the solvent 
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Figure 5.5: topographic (right) and phase [152] AFM images of a) 1/2, b) 1/5, c) 1/10 felodipine/PVP 
mixture produced by the microarray printing device. 
5.5.2 Scanning Thermal Microscopy 
Figure 5.6 shows the SThM results of a spot produced by the microarray printer and 
the DSA 100. In both graphs, there is single transition point, which increases as the 
concentration of polymers indicating intimate mixture of the drug and the polymer. 
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Figure 5.6: comparison the SThM results produced by the microarray printer and by the GeSim 
dispenser. 
5.5.3 Confocal Raman Mapping 
The chemical images of felodipine/PVP mixtures are illustrated in Figure 5.7,Figure 
5.8 andFigure 5.9. The differences among the spectra which allow the plot of the 
chemical images of the samples are based on the intensity of the spectra . In all the 
cases, the green spectra correspond to an area with the lowest quantity of material, 
whereas the red spectra is the highest quantity of material as the peaks are more 
intense. As all the model spectra have peaks from the felodipine and PVP, the 
samples is homogenous without phase separation or any other chemical 
modification at least at the sale of observation (approx 500nm). 
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Figure 5.7: a) Eigenvalues versus principal components number, b) the model spectra used to plot the 
chemical map, c) optical microscope image, d) chemical map of the felodipine/PVP mixture 1/10 ratio . 
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Figure 5.8: a) Eigenvalues versus principal components number, b) the model spectra used to plot the 
chemical map, c) optical microscope image, d) chemical map of the felodipine/PVP mixture 1/5 ratio . 
110 
5. Production of array of a single API 
000 
'oo 
600 
300 
200 
100 lt3 
a) 0L;-_--!== ;:" '= ' = O " ~ = , ! = : : : : : ; = = ! ! : : ! !
3 • 5 
b) 
Pmcipa/ Compone,. Nl..mbef 
· 1 
d) 
·200 o 
Figure 5.9: a) Eigenvalues versus principal components number, b) the model spectra used to plot the 
chemical map, c) optical microscope image, d) chemical map of the felodipine/pVP mixture lIs ratio . 
5.5.4 Tof-Sims 
Figure 5.10 shows the chemical image for of a pair of droplets of all the various 
concentration produced. As it is shown from the chlorine chemical distribution, 
felodipine is distributed evenly on the surface with perfectly reproducibility among 
the samples. Finally, it was shown that the fluorinated compound remained on the 
substrate without being mixedwith the solute during the solvent evaporation. 
111 
5. Production of array of a single API 
Figure 5.10: Tof-Sims images of two droplets of felodipine/PVP mixtures of ratio a) 1/10, b) 1/5, c) 1/2 
produced from microarray printing machine. The left image of each pair show the substrate using 
CSH8F as a marker. The middle image corresponds to the position of the API using CI as a marker and 
the third image corresponds to the total ion. 
5.5.5 Dissolution studies 
Figure 5.11 shows the dissolution profiles of felodipine from a microarray of 
felodipine/PVP mixtures and the pure API. In the present study, the dissolution rates 
of felodipine in the FASSIF solution were significantly faster than that of the pure API. 
The drug in the mixture with the PVP is released completely and very rapidly after its 
immersion in the medium. 
20 40 60 80 100 120 
time (min) 
Figure 5.11: dissolution profiles of pure felodipine, and the sprayed felodipine/PVP mixture 1/5 and 
1/10 mixtures. 
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5.6 Discussion 
Atomic force microscopy shows that the sample is homogenous without any phase 
separation at the nanoscale or indication of crystallization. It is worth mentioning, 
the difference in the colour in the phase images comes from the topographical 
variations of the sample. The holes in the sample appear brighter in the phase image. 
This is because, as the tip goes inside the hole, the interactions between the tip and 
the sample increase due to the increase in tip-sample contact area. This is 
encouraging data, as it indicates that the sample is similar to the those produced in a 
smaller scale. 
Moreover, the SThM results are remarkably comparable for drops produced by both 
the devices. They both gave the same pattern with the sample produced by the 
microarray printer providing lower values for the thermal transitions. A possible 
reason is that the sample produced by the microarray printing, due to the 
hygroscopic nature of PVP absorbed more water than the ones produced by the 
GeSim dispenser as they are contain more material, reducing the glass transition 
temperature of the sample. Besides, it was shown from previous publication that the 
increasing the water uptake of the samples results to a decrease in glass transition 
temperature of the polymers [183] which was also confirmed for felodipine/PVP 
mixture [123]. 
In terms of the confocal Raman mapping, the chemical images were plotted, 
separated in three principal components, as the samples consist of three different 
compounds felodipine, pvp and glass. Before concluding to this number of PCs, the 
chemical images were separated in more factors where it was confirmed that the use 
of more than three factors does not offer any more increase in the detection 
resolution. This indicates that there are no different forms of the three components 
in the sample and that an intimate amorphous mixture of PVP and felodipine has 
been created. The separation of the components occurred based on the intensity of 
the peaks and not on the quality differences. 
There are limited numbers of papers which investigate the dissolution of felodipine 
in FASSiF solutiOn. Felodipine is neutral and exhibits a water solubility of 11J81ml at 
37°C. However, FASSIF increases the solubility of felodipine by a factor of ca. 50 
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[184] . These experiments showed that the pure felodipine dissolves extremely 
slowly. Even in two hours only 3% of the drug was dissolved. In contrast, when 
felodipine is associated with the PVP, it releases completely and rapidly. The rapid 
dissolution of the mixtures may be a result of the dispersed state that the API in the 
polymer matrix and the low quantity of material deposited in a single spot which 
increases the surface area which is in contact with the dissolution medium. The 
reduction of particle size is a common technique used to improve the dissolution of 
an ingredient [185-186]. It is interesting also the fact that the felodipine dissolves 
very rapidly, contrary to previous work where the API when associated to PVP 
dissolves in a gradual manner. This is because each spot act as an independent 
formulation which due to the quantity will be dissolved rapidly. 
However, when blank FASSIF was used as a medium, felodipine did not dissolve. In 
Figure 5.12 the optical microscope image and the Raman spectrum of the remaining 
material are illustrated. From the Raman spectrum, it is shown that the remaining 
felodipine is amorphous due to broadness of the amino peaks. Also, the peaks of the 
polymer have disappeared indicating that only the API remained on the surface. The 
optical microscope image, shows that some of the material was released as only 
approximately half of the dots remains, again most probably because of the PVP 
dissolution. The most probable reason why felodipine is not released from the 
formulation is the high concentration solution which was used in the sprayed droplet 
and the hydrophobic substrate . These two parameters may result the felodipine 
becoming associated with the · substrate, inhibiting dissolution. This belief is 
supported by the fact that reducing the concentration of the API in the solution of 
the 1/2 felodipine/PVP allows the drug to be released as shown in the previous 
chapter. 
a) 
Figure 5.12: a) optical microscope image of the remaining after the dissolution product, b) Raman 
spectrum of the the remaining product. 
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S.7 Conclusions 
In this chapter the production of a proper solid drug dosage form based on the 
current technology of inkjet printing was described. This technique can be the 
predecessor of a real tailored therapy. Its flexibility to spray samples with different 
concentration in API, which individually will follow a different dissolution profile, 
could allow tuning of the release drug profile according to the patient's needs. 
This chapter showed that the production of a proper dosage form with the current 
technology is feasible. However the restriction to increase the concentration of the 
sprayed solution can limit the application of the technique. 
In this chapter, microarrays of felodipine and PVP mixtures were prepared. AFM and 
confocal Raman data confirmed that the product is similar to what is produced by 
the GeSim dispenser as described in chapter 3, namely homogenous and amorphous. 
The release of the API in the FASSIF solution is rapid whereas In contrast it Is almost 
insoluble in blank FASSIF. 
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6. Production of arrays of 
multiple APIs 
6.1 Introduction 
In this chapter, it is attempted to produce a proof of principal combination therapy 
by inkjet printing. The therapy contains two active pharmaceutical ingredients 
captopril and hydrochlorothiazide. These two drugs are combined in a dosage form 
and are marketed by the brand name Capozide™. 
A challenge that needs to be faced in order to prepare a proper product is to control 
the release of these APls as both are freely soluble in the medium used. For this 
purpose PLGA was used to create a polymer matrix which would control the release 
of the APls. However, PLGA produces more viscous solutions than PVP, which was 
used in the case of felodipine. Hence in the previous chapter the main technical 
issue, we needed to overcome was the ejection of highly concentrated solutions. 
Also, due to the fact that PLGA produces a more viscous solution than PVP only 
10mg/ml of PLGA was able to be sprayed. 
6.2 Capozlde formulation 
Capozide™ for oral administration combines two antihypertensive drugs, captopril 
and hydrochlorothiazide. Capozide™ is available in four formulations of captoprll 
with hydrochlorothiazide 25 mg with 15 mg, 25 mg with 2S mg, SO mg with 15 mg, 
and SO mg with 25 mg. 
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The rationale for using fixed-dose combination therapy, as in the case Capozide™, is 
to obtain increased blood pressure control by employing two antihypertensive 
agents with different modes of action and to enhance compliance by using a single 
tablet that is taken once or twice dally. Monotherapy is effective in achieving the 
target goal in only about 50 percent of patients, treatment with two or more agents 
from different pharmacologic classes Is often necessary to achieve adequate blood 
pressure control. Specifically, by using a single therapeutic, the efficacy increases by 
the dose of a particular agent. However, as you increase the dose of that same 
agent, there is a simultaneous increase in dose-dependent side effects. Using low 
doses of two different agents can also minimize the clinical and metabolic effects 
that occur with maximal dosages of the individual components of the combined 
tablet [187-188]. 
The rationale behind the utilization of combination of captopril and 
hydrochlorothiazide Is to increase the output urinary levels of potassium. More 
specifically, thiazides cause a reduction in intracellular sodium (Nal) and In intra- and 
extracellular potassium (1<., Ke). Since In many patients Ke losses are greater than KI 
losses, the K/Ke ratio (which is directly related to membrane potential and thus to 
vascular tone) increases. Captopril also reduces Nal but its effects on Ke and I<. are 
quite different from those of thiazides. Captopril in fact causes an increase in I<. 
inducing a net increase in KJKe. This increase can also be observed when captopril is 
given in combination with thiazide. Therefore the combination of captopril and 
hydrochlorothiazide has an additive effect on Nab and increases KJKe in the vast 
majority of patients [189J. Also, captopril can prevent hypokalaemia and 
hyperuricaemia observed with hydrochlorothiazide alone in addition to its 
antihypertensive synergy [190J. 
6.3 PLGA and Pluronlcs In drug delivery 
PLGA is a well-known biodegradable and biocompatible polymer with a history of 
safe use in orthopaedics [191], bone plates [192], and extended release 
pharmaceuticals [95, 193-196]. Macromolecular drugs such as proteins [197-198], 
peptides [198-199], genes [200], vaccines and antigens can be successfully 
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incorporated into PLGA or PLGA-based nano/microparticles [201]. PLGA degrades 
chemically by hydrolytic cleavage of the ester bonds in the polymer backbone. The 
degradation products lactic acid and glycolic acid are water soluble non-toxic 
products. Polymer degradation influenced by amorphous/crystallinity, hydrophilicity, 
molecular weight, and the presence of excipients play an important role [202] . 
Consequently, the drug release kinetics from the PLGA are mainly determined by 
both diffusion of drug through the preformed aqueous pores and interconnected 
channels, as well as an erosion of the polymer matrix. Thus, the drug release rate can 
be affected by the inherent drug properties such as molecular size and water 
solubility and initial microsphere morphologies such as porosity and tortuosity. 
Triblock copolymers of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO) 
(PEO-b-PPO-b-PEO), available under trade name " poloxamer" or "Pluronic," are 
recognized as pharmaceutical mUltipurpose excipients capable of increasing aqueous 
solubility and stability of drugs. These amphiphilic copolymers are nontoxic and 
commercially available in a wide range of molecular weights and architectures, which 
determine their hydrophilic/lipophilic properties and hence show the ability to form 
nanoscopic core-shell structures in water. The incorporation of drugs into the core of 
the micelles formed by Pluronic· results in increased solubility, metabolic stability 
and circulation time for the drug [203] . 
Nowadays there is a plethora of research papers that investigate the incorporation of 
PLGA with pluronic. These papers mainly focus on the preparation of micro- and 
nanoparticles which encapsulate the biologic compound protecting it not only from 
the environment but also from its inactivation that may be caused by its 
incorporation with PLGA only [204-206] . 
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118 
Production of arrays of multiple APls 
6.4 Mathematical models In drug release from polymer matrix 
There are number of mathematical models used to describe the release of the API 
from a polymer matrix [43-44, 48, 207]. The main drug release mechanisms are drug 
diffusion from the non degraded polymer (diffusion controlled system), enhanced 
drug diffusion due to polymer swelling (swelling-controlled system) and drug release 
due to polymer degradation and erosion (erosion-controlled system). Mathematical 
modelling concerns unifications of all the individual parameters involved in the drug 
release, which involves not only mass transport and chemical processes but also 
design parameters such as the device geometry and drug loading. 
The zero-order model expresses the dissolution from pharmaceutical dosage forms 
which do not disaggregate and release the drug slowly. Zero order describes a 
system where the release is independent from the concentration (eq. 6.1). First 
order release rate is concentration dependent (eq. 6.2). The Higuchi model has 
developed in 1963 and it was the first to specifically describe the release of drugs 
from a polymer matrix. It is expressed as a square root of time dependent process 
based on Fickian diffusion (eq. 6.3) [208]. The Hixson-Crowell cube root law (eq. 6.4) 
describes the release from systems where there is a change in surface area and 
diameter of particles or tablets (Hixson and Crowell, 1931). 
(6.1) 
This relationship can be used to describe the drug dissolution of several types of 
modified release pharmaceutical dosage forms, as in the case of some transdermal 
systems, as well as matrix tablets with low soluble drugs in coated forms, osmotic 
systems [133, 209-210]. 
logQo = l o g Q , - ~ . 3 0 3 3
(6.2) 
This relationship can be used to describe the drug dissolution in pharmaceutical 
dosage forms such as those containing water-soluble drugs in porous matrices (211]. 
(6.3) 
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This relationship can be used to describe the drug dissolution from several types of 
modified release pharmaceutical dosage forms, as in the case of some transdermal 
systems [212] and matrix tablets with water soluble drugs [213]. 
(6.4) 
This model can be applied to a pharmaceutical dosage form whose drug release rate 
is proportional to the surface area of dosage form, such as in erosion-dependent 
release systems [44, 214] . 
In the above equations 00 is equal to the initial amount of drug, Ot is the cumulative 
drug release at time t, ko the zero order release constant, k the first order release 
constant, kH the Higuchi constant and kHC the Higgson-Crowler release constant 
Finally, a simple empirical equation from Korsmeyer et al was introduced to describe 
the release behaviour from controlled release polymeric matrices. 
(6.5) 
The value of n gives an indication of the release mechanism. Hence it was stated that 
n is 0.5 for Fickian diffusion, 0.5 < n > 1.0 for non- Fickian transport and 1.0 for case" 
transport. When n > 1.0 super case II transport is apparent. Case" transport involves 
polymer dissolution and chain disentanglement. In the case of a cylinder n = 0.45 
instead of 0.5 and 0.89 instead of 1 must be used [2151. 
6.S Alms - Objectives 
The aim of this chapter Is to produce a combination therapy based on inkJet printing. 
Captopril and HCT mixtures with PLGA were prepared by means of Inkjet printing and 
also by depOSition solution with pipette. The deposited products were characterised 
by AFM and Raman. Finally the release of the drugs was investigated using HPLC. 
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6.6 Materials - Methods 
6.6.1 ftfaterials 
Captopril, hydrochlorothiazide, poly(lactic-co-glycolic acid) (85:15), Pluronic F-127 
and DMSO 99% anhydrous were purchased from Sigma-Aldrich. Flutec fluid was 
purchased from F2 chemicals (Lancashire, UK). 
6.6.2 ftfethods 
6.6.2.1 Preptlratlon 0/ solutions 
Captoprll 
To deposit mixtures of captopril and PLGA onto substrate, solutions of captopril and 
PLGA were prepared by dissolving them into a mixture of chloroform, ethanol and 
DMSO (75/18/7). Chloroform was used to dissolve PLGA. Ethanol was used to 
dissolve captopril and to disperse DMSO, as DMSO is not miscible with chloroform. 
Finally DMSO was used to increase the boiling point to the solution to avoid any 
possible cloggage in the dispenser. The ratios of captopril to the polymer were 30/70 
and 50/50 (w/w), whereas the concentration ofthe polymer was 20mg/ml. 
Hydrochlorothiazide 
Solutions of hydrochlorothiazide with PlGA were prepared by dissolving them into a 
mixture of acetone, and DMSO (93/7). Both HCT and PlGA are soluble in acetone. 
DMSO was used to increase the boiling point of the solution to avoid clogging the 
dispenser. 
6.6.2.2 Dispensing 0/ solutions 
The solutions were dispensed using either by a or a microarrays printer. When the 
samples were deposited by using pipette, the solutions were contained 20mg/ml 
PLGA in both the case of captopril and HCT. 2J.l1 of solution was deposited on each 
spot of the microarray. 
When the samples were deposited by means of the microarray printer the solutions 
were contained 10mg/ml PLGA. Captopril solution was sprayed without PLGA, 
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whereas HCT was sprayed with PLGA and Pluronie F-127 in a ratio of 50/45/5 
HCT /PLGA/Pluronie. 
Microarrays were formed using an ink-jet printer (i) (SeiflexarrayerSS, Seienion). 10 
ml of wash solution (Acetone) was flushed through the system at 60 J.ll/s. Nozzle was 
then connected to the system and flushed with a further 2 ml of acetone at 10 J.l1/s. 
The nozzle used was a 90 J.lm hydrophobic nozzle. Printing conditions were 1S!!C base 
temperature, 22!!C air temperature, 34% humidity, 509 Hz frequency, 164 V pulse 
and 64 J.lS pulse width. The number of spots was 16)(49, where 300 droplets were 
deposited on each spot. 
6.6.2.3 Atomic Force Microscopy 
AFM analysis was performed in tapping mode using a Dimension 3000 (Nanoscope 
ilia controller, Veeco, CA). Tap300 cantilevers were used (Budget Sensors, Sofia, 
Bulgaria). SPIP software (Image Metrology, Denmark) was used to analyse the 
images. 
6.6.2.4 Confocal Raman 
Confocal Raman studies were performed using a Jobln-Yvon/Horlba micro-Raman 
spectrometer, by means of red laser with 632nm wavelength and 600 1/nm grating. 
The spectrometer is equipped with an Olympus microscope BX41. 
Raman spectra were obtained using red laser with 632nm wavelength and 600 1/nm 
grating. The acquisition time was 8sec with 5 repetitions. 
Confocal Raman mapping has been applied to captopril/PLGA, HCT/PLGA and 
HCT/PLGA/Pluronic mixtures. The sample profiling at step increment In these case 
were performed on 12J.lm in x- and y- directions with 3 sec exposure time with 2 
repetitions. Raman data were collected through a 100)( objective. The data analysis 
was carried out in the NGLabSpec software. After acquisition multivariate analysis 
was carried out using routines from the software. Eigenvalues and PCA when it was 
necessary were carried out by means of Solo+MIA software (Eigenvector, USA). 
6.6.2.5 Dissolution study 0/ the mlcroarray 
The dissolution rate of the microarrays was measured using a beaker shaken with a 
shaking stage. Each sample was placed in SGF solution without enzyme in a 
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concentration of 0.035 mg/m/. The SGF solution was prepared by dissolving 0.05M 
NaCI in deionised water and adjusted it at pH 1.5 with HC/. At predetermined time 
intervals, samples of 1ml were withdrawn from the dissolution medium, filtered 
through 0.211m syringe filter and assayed using the HPLC method for the drug. 
The investigation of the dissolution profile of Capozide ™ tablets was performed in a 
USP paddle apparatus 2 at a paddle rotation speed 50rpm at room temperature in 
900ml SGF solution without enzyme. 
6.6.2.6 HPLC analysis 
The chromatographic system was an HP agilet 1050. The chromatographic column 
was a C8 gemini analytical column (100mm x 4.6mm I.D., particle size 5I1m). The 
mobile phase consisted of acetonitrile and 0.1% phosphate buffer (25/75 v/v) . The 
mobile phase was determined so that both captopril and HCT was able to be 
detected simultaneously (Figure 6.2) and also because captopril exhibits the 
maximum stability on pH below 4 [134] . 
The mobile phase was also filtered with 0 . 2 ~ m m autofilter. The autosampler was set 
up to make 20111 injections, every 6mins. The flow rate of the mobile phase was 
1ml/min and the detection was at 218nm at 40°C. 
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Figure 6.2: Representative chromatogram of the of the tablet. The large peak at 2.23 minutes 
corresponds to the HCT and the samller peak at 2,67 corresponds to captopril. 
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6.7 Results 
6.7.1 Atomic Force Microscopy 
6.7.1.1 Captopril 
The product obtained when captopril and PLGA of different ratios were deposited 
using pipette is illustrated in Figure 6.3 . When PLGA was sprayed alone the 
deposited material appeared amorphous and homogenous (Figure 6.3a) . However, 
the addition of captopril resulted in the formation of small circular features on the 
surface and an inhomogeneous mixture (Figure 6.3b,c) . These features are likely to 
be captopril exposed on the surface. 
Figure 6.3: Topographic (left) and phase (right) AFM images of Captopril/PLGA mixtures of a) 50/50, 
b)30/70 and c) after the dissolution of 30/70 captopril/PLGA mixture for 10sec in water. 
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6.7.1..2 Hydrochlorothiazide 
AFM images of the mixture of HCT with PLGA prepared by pipetting and by the 
microarray printer are illustrated in Figure 6.4. In all the cases the phase images 
show that there can be phase separation between the two components. The 
addition of pluronic resulted to a phase separated mixture (Figure 6.4c). The product 
occurred by using the microarray printer appeared homogenous without phase 
separation and with no sign of crystallization (Figure 6.4d). 
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f) 
Figure 6.4: Topographic (left) and phase (right) AFM images of a) HCT/PLGA = 50/50 produced by 
pipette b)HCT/PLGA = 30/70 produced by pipette, c)HCT/PLGA =20/80 produced by pipette, 
d)PLGA/Pluronic = 90/10 produced by pipette, e) HCT/PLGA/Pluronic = 50/47/3 produced by microarray 
printerf) HCT/PLGA/Pluron ic = 20/75/5 produced by pipette. 
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6.7.2 Raman Mapping 
The spectra of pure captopril, PLGA, HCT, Pluronic and substrate are illustrated in 
Figure 6.5 Figure 6.6. In the mixture of captopriljPLGA the characteristic peaks that 
can be used to distinguish the two compounds from the mixture are the two 
carbonyl peaks of captopril at 1619cm·1 and 1728cm·1 and the carbonyl peak of PLGA 
at 1768cm·1. Also, good markers can be the peak at 920cm·1 corresponding to the 
ring breathing of captopril and the peak of PLGA at 1130cm·1 corresponding to the 
asymmetric vibration of C-O-C groups of PLGA. 
In terms of the mixture of HCT/PLGA and HCT/PLGA/Pluronic, the compounds could 
be distinguished from the peak at 1768cm·1 for PLGA, 1600cm·1 for HCT and 847cm·1 
or 1478cm·1 for pluronic. 
' Captoprll sprayed 
· PLGA 
Figure 6.5: Raman spectra of Captoprii sprayed and PLGA in the area of 850 - 1800cm·1. 
1\ 
' PLGA 
' P luronic 
· HCT sprayed 
Figure 6.6: Raman spectra of sprayed HCT, PLGA and Piuronic in the area of 850 - 1800cm·1 
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6.7.2.1 Captopril 
Figure 6.7 shows the Eigenvalues for each principal component. It is observed that 
the Eigenvalues were reduced dramatically after the first factor and were almost 
zero after the third factor which indicates that the contribution of more than three 
factors is limited. Hence, the chemical map of the product has been created by using 
two principal components (pes). 
From the model spectra in Figure 6.7b, it is clear that the red spectra corresponds to 
areas with a higher concentration of captopril, as the characteristic peaks of PLGA 
are less intense and moreover the carbonyl peak of PLGA covered by the carbonyl 
peak of captopril. 
Also, in Figure 6.7c the optical microscope image is illustrated with the rectangular 
box are the data limits for the chemical image. From these two images, it is clear that 
there is a correlation of the topographic figures in the optical microscope image with 
the chemical data in the chemical image. 
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Figure 6.7: a) eigenvalues plot versus Principal Components numbers, b) model spectra used to create 
the chemical map, c)optical microscope image of deposition of CaptopriI!PLGA=50/50 mixture, d) 
Chemical image of the Captopril/PLGA = 50/50 mixture. 
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6.7.2.2 Mlcroarray (HCT/PLGA/Pluronlc = 50/47/3) 
As shown from the eigenvalue plot versus the PC numbers, PCA analysis suggests 
using 3 factors to create the chemical image of the sample. However, in this case 
four PCs have been found to be more suitable, as by using this number of factors an 
additional chemical characteristic of the product appeared model spectra (blue 
spectra). The two most characteristic peaks of the Raman spectra of the samples are 
the NH2 bending vibration of HCT corresponded by the strong peak at 1597cm-1 and 
the carbonyl peak of PLGA corresponds to the peak at 1758cm-1• 
The yellow and the red spectra are separated based only on their intensity as they 
look qualitively similar. However, the areas corresponding to the yellow spectra are 
more concentrated in the polymer, than the areas corresponding to red spectra, 
since the ratio of the characteristic peak of HCT to the peak of PLGA are less than in 
red API. The purple area contains the API only, whereas in terms of the green 
spectra, it has the less intensity and the peaks are not so clear. The most Interesting 
spectra is the blue. In the blue spectra, the carbonyl peak has moved towards lower 
wavenumbers which indicate hydrogen bonding of the carbonyl peak of the PLGA. 
This hydrogen bonding can occur between the carbonyl group of PLGA and either the 
NH groups of HCT or the OH groups of pluronic as discussed in chapter 3. 
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Figure 6.8 : a) eigenvalues plot versus PCs numbers of the HCT/PLGA/Pluronic = 50/47/3 mixture 
produced by the microarray printer b) model spectra used to create the chemical map. The green 
spectrum corresponds to the background, the pink one corresponds to areas with pure API, the red and 
yellow spectra correspond to areas with HCT/PLGA mixture and the blue spectrum correspond to areas 
where the HCT interacts with PLGA, c)optical microscope image of deposited product d) Chemical image 
of the m ixtu re. 
6.7.2.3 Pippete produced /ormuoltions 
PLGA/Pluronic = 90/10 
The eigenvalues plot versus the PC numbers for the PLGA/Pluronic mixture show that 
the first PC is enough to show the obtained spectra . This is proved by the model 
spectra used to plot the chemical map as it is clear that the model spectra are 
separated based on the intensity of the peaks. However, due to their low detection 
signal the peaks of pluronic were not revealed . Finally, the optical microscope image 
shows that the product is evenly distributed along the substrate. 
To reveal the position of pluronic, by using the Solo+MIA software, PCA was 
employed. Peaks of pluronic appeared in the 8th PC whereas the previous were PCs 
found to contain peaks from PLGA. As a representative PC of this kind, the 2nd PC is 
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illustrated in Figure 6.10. The chemical image of pluronic seems to be more reliable 
than this method because it is nicely reproduced in the 8th Pc. 
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Figure 6.9: a) eigenvalues plot versus PCs numbers of the HCT/PLGA = 20/80 mixture produced by the I microarray printer b) model spectra used to create the chemical map, cL optical microscope image of 
deposited product d) Chemical image of the mixture. 
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Figure 6.10: a) Chemical image of PC2, b) spectrum of PC2, c) chemical image of PC8, d) spectrum of 
PC8. The asterisks are the characteristic peaks of pluronic. 
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HCT/PLGA ::: 20/80 
In Figure 6.11a the Eigenvalues plot with the principal components is illustrated. 
From this plot, it is clear that the factors that can contribute to the obtained spectra 
are the first three. Figure 6.11c shows the area of the spot that was mapped. The 
chemical map has been created by separating the spectra in to three principal 
components. Hence, the areas corresponding to red model spectrum are areas 
contain only HCT since the characteristics peaks of PLGA such as the carbonyl group 
at 176Ocm·1 are missing In model spectra. The green and blue area contain both HCT 
and PLGA as the model spectra corresponding to these contain the characteristic 
peaks of HCT and the characteristic peak of PLGA at 1760cm-1 (Figure 6.11b). 
However, the use of four factors produced the most accurate map of the product. 
This was confirmed when a spectrum was taken in a random position in the yellow 
area in the sample (Figure 6.11d). From Figure 6.11g the spectrum at this position fits 
better to the yellow model spectra which does not contain PLGA peaks rather than 
the green spectrum of the model with three factors which contain peaks of the 
PLGA. 
Finally, based on this analysis, and in combination with the optical microscope image 
(Figure 6.11c), it is clear that the API is gathered in the centre of the product. 
Specifically, the yellow and purple model spectra are related to the spectrum of pure 
HCT in areas where the API is highly concentrated. Finally, the optical microscope 
image shows that most of the material was gathered at the edge the spot. The 
chemical image along with the optical microscope Image shows that PLGA moves 
tends to gathered at the edge of the spot. 
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Figure 6.11: a) Eigenvalues plot versus PCs numbers of the HCT/PLGA = 20/80 mixture produced by 
the microarray printer b) 3 model spectra used to create the chemical map. The red spectrum 
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HCT/PLGA mixture c)optical microscope image of deposited product d) Chemical image of the 
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Her /PLGA/Pluronic = 20/75/5 
In the case of the mixture of HCT/PLGAjPluronic mixture the PCA analysis showed 
that two factors contribute to the spectra obtained (Figure 6.12a). Hence, the 
chemical map of the spot has been separated in to two PCs. 80th components 
contain peaks of both HCT and PLGA. Unfortunately, Raman was not able to 
distinguish the pluronic's characteristic peak due to its low concentration and 
because most of the pluronic peaks are overlapped from those from PLGA and HCT. 
The red model spectra express areas which contain the less material. Also it is 
interesting to notice the two shoulders at the 1720cm·1 and at the 1780cm-1 in the 
green spectrum. However, the peak at 1720cm-1 it is most likely noise which was 
picked up by the multivariate analysis. Also, the optical microscope image shows 
that the compounds have been distributed evenly during the evaporation. 
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Figure 6.12: Eigenvalues plot versus PCs numbers of the HCT/PLGA/pluronic = 20/75/5 mixture produced by 
the microarray printer b) 3 model spectra used to create the chemical map, c)optical microscope image of 
deposited product d) Chemical image of the mixture. 
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HCT /PLGA = 50/50 
The Eigenvalues plots versus the number of principal components are illustrated in 
Figure 6.13a. According to this plot, three factors contribute to the obtained spectra 
mostly. Figure 6.13b and c illustrate the chemical map of the spot and the three 
components used to plot the chemical image. The green spectrum corresponds to 
areas with low quantity of materials or to areas where the laser beam lost its focus. 
The red spectra correspond to areas which consist of HCT only whereas the blue 
spectra contain both PLGA and HCT as the characteristics peaks of HCT and PLGA 
coexist. 
Finally, the chemical and optical microscope image shows that the centre of the 
product is occupied by HCT whereas PLGA has been moved to the edge where most 
of the deposited material has been gathered to the edges. Similarly the optical 
microscope image shows that most of the deposited material was gathered to the 
edge. , 
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Figure 6.13: Eigenvalues plot versus PCs numbers of the HCT/PLGA = 50/50 mixture produced by the 
microarray printer b) 3 model spectra used to create the chemical map. The green spectrum correspond 
to the background, whereas the blue and the red correspond to areas with HCT/PLGA and pure HCT 
respectively c)optical microscope image of deposited product d) Chemical image of the mixture. 
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6.7.3 Raman spectra 
6.7.3.1 Hydrochlorothiazide 
To investigate the physicochemical nature of the hydorchlorothiazide, Raman spectra 
of the products were taken at two random places at the centre and the edge of the 
samples. 
The most important groups in the mixture of HCT and PLGA are the NH groups and 
the SO groups of HCT and the carbonyl group of PLGA. The NH groups occurred at 
the area between 3100-3700cm'1, whereas the SO groups are assigned to peaks at 
1300cm·1 corresponding to the asymmetric vibration and at 1165 cm-1 corresponding 
to the symmetric vibration of the group in question. Finally the carbonyl group of 
PLGA occurs at 1765 cm-1• 
From the Figure 6.14,6.15, Figure 6.16 and Figure 6.17c, It is clear in all samples that 
the broadness of the amino peaks of HCT compared with the powder indicates an 
amorphous nature of the product. Also, in the mixtures HCT/PLGA 20/80 and 
HCT/PlGA/PIuronic the peak assigned to the symmetric vibration of SO group has 
moved slightly to higher wavenumbers from 1164cm-1 to 1174cm-1 in the case of 
HCT/PlGA = 20/80 and to 1172 cm-1 when pluronic is added. In the case of the 
HCT/PlGA SO/SO the SO peaks of the spectrum obtained from the edge and the 
centre of the product, are in the same position. Nevertheless, they both have been 
shifted slightly to higher wavenumbers than the sprayed HCT from 1166cm-1 to 
1171cm-1. In the mixture produced by the microarray Finally, the carbonyl group of 
PlGA remains in the same position with the carbonyl group of the unprocessed 
PlGA. In terms of the amino groups, the broadness of the peaks makes the analysis 
difficult. However in all the cases they seem to remain in the same position. 
However, in the case of HCT/PlGA SO/SO both the peaks corresponding to the amino 
groups looks to have been moved to lower wavenumbers. 
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Figure 6.15: Raman spectra of HCT/PLGA 20/80 taken from the edge, from the centre, pure HCT and 
PLGA with zoom at the area of b) 50 vibrations and c) amino groups. 
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Figure 6.16: Raman spectra of HCT/PLGA a) 50/50, b) 30/70, c) 20/80, d)HCT/PLGA/Pluroic = 20/75/5, e) 
product from the microarray printer with zoom at the area of II) SO vibrations and III) amino groups. 
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Figure 6.17: Raman spectra of HCT/PLGA a) 50/50, b) 30/70, c) 20/80, d)HCT/PLGA/Pluroic = 20/75/5, e) 
product from the microarray printer with zoom at the area of 11)50 vibrations and III) amino groups .. 
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6.7.3.2 Captopril 
In the captopril powder the c=o stretching vibration of the carboxylic group of 
captopril is assigned at 1745 cm-l and the C=O stretching vibration of the amide 
group at 1603 cm-l and at 1583cm-l . In the sprayed drug the former peak has been 
shifted to 1727 cm-l whereas the latter has been shifted to 1616 cm-l. Moreover, due 
to the broadness of the peak, it is not clear if both the peaks of the amide of the 
crystalline pwoder have been shifted. 
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Figure 6.18: Raman spectra of powder captopril, Ca/PLGA = SO/SO mixture produced by pipet and pure 
captopril produced by the microarray printer with zoom in the carboxylic region . 
6.7.4 Dissolution studies 
Figure 6.19 shows the effect that PLGA has on the dissolution rate of captopril. When 
captopril was immersed in blank SGF, it is dissolved completely in less than three 
minutes. The addition of PLGA results in a more extended release of the API. 
Increasing the concentration of PLGA 70% in the mixture causes the captopril to be 
released more slowly, where even after 3hrs the drug has released 60% only of the 
drug. In the mixture of equal concentrations of API and PLGA there is an initial burst 
release of the API and after the fifth minute the drug is released in an extended 
manner where it is released completely after 3hrs. 
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Figure 6.19: Dissolution profi le of Captopril, Captopril/PLGA 30/70 and Captopril/PLGA 50/50. 
The influence of PLGA in the release of API is illustrated in the Figure 6.21. Pure HCT 
is dissolved rapidly in the blank SGF. The utilization of PLGA in the mixture results in 
an extended release of the API. Hence, at the lower concentration of the API the 
drug is released with the slowest rate where after two hours only 20% has been 
released in the medium. Increasing the concentration of API in the mixture, results in 
an increased dissolution rate. However, even after two hours the API being released 
is 70% of the initial loading. 
The addition of Pluronic results in a much more rapid release of the API. Hence, both 
when the API consists the 30% and when the API consists of the 20% it is released 
completely after the 40 minutes. 
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Figure 6.21: a) dissolution profiles of HCT/PLGA 20/80 and HCT/PLGA/Pluronic 20/75/5, b) dissolution 
profiles of HCT/PLGA 30/70 and 30/65/5. 
6.8 Discussion 
AFM data showed phase separation for both the mixtures of captopril and HeT with 
PLGA. For captopril/PLGA the phase separation appears as small dots on the surface 
of the polymer matrix. This can be realised when after its dissolution in water, the 
dots were replaced by small depressions indicating that the captopril was dissolved. 
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In the mixtures of HCT/PLGA the two compounds are phase separated. This 
phenomenon was observed by AFM also when the mixtures were prepared using the 
piezo- dispenser from GeSim (chapter 3.12). However, it is worth noticing that the 
phase separated portion of the sample is a low percentage of the whole sample. The 
observed phase also is consistant with the burst effect in the dissolution studies for 
both captopril and the HCT, since the API which is phase separated will dissolve 
rapidly and then dispersed in the polymer in a more gradual manner. It is also 
interesting that the samples with pluronic produced by pipetting exhibited phase 
separation and those produced by the microarray printer were homogenous. The 
reason for this may come from technical issues regarding taking AFM images. More 
specifically, the shape of product produced by the microarray printer contains lots of 
curved surfaces which make the imaging with AFM more difficult. Therefore, it is 
likely that the phase separation occurred in the areas where AFM could not work. 
Also, the mixture of pluronic and PLGA produced a non-homogenous mixture. This is 
consistent with previous results where the use of 2% of pluronic resulted in a 
homogenous product whereas 50% of pluronic caused a phase separation on the 
surface [216}. 
The chemical map of the samples were processed using direct classical least square 
(DCLS) based on the algorithms of the NGLabspec. In order to choose the number of 
factors that contribute to the plot of chemical mapping, the Eigenvalues of each 
principal component was analysed. As in the previous chapters the PC Eigenvalues 
sharply decrease after the first PC. Based on this behaviour, it can be concluded that 
it is quite likely that two components exists which is plausible like in chapter 3 there 
is no pure polymer areas. The factors which have been used to plot the chemical 
image have been chosen in such a way that the model spectra will reveal all the 
necessary chemical information. However, in the sample containing mixture of HCT 
PLGA and Pluronic, Pluronic was not able to be detected due to its low detectable 
signal and because its strongest peaks were covered by the peaks of HCT and PLGA. 
However in the case of the PLGA/pluronic mixture, PCA was able to reveal pluronic. 
The interesting and the unexpected result was that a clear pattern of the peaks of 
pluronic appeared in the ath PC very far away from the first PC which was suggested 
by the Eigenvalues versus PC numbers plot. By using DCLS from the NGLabspec 
software, it is likely that the small shoulder at 849cm·1 belongs to the strong pluronic 
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peak. However, the spectrum of the pure PLGA has a small peak on this wavenumber 
and as the concentration of PLGA is 9 times higher it may belong to the PLGA. Hence, 
by using the MIA software and PCA analysis it was able to reveal the whole pattern 
of the pluronic. 
Raman mapping revealed that the samples prepared by both the microarray printer 
and depositing with pipette have different physicochemical properties at their 
surfaces. The samples HCT/PLGA prepared by the microarray device are phase 
separated, a phenomenon which has been first introduced in chapter 3 In the 
samples prepared by the GeSim dispenser. Samples prepared by depositing the 
solution with pipette are phase separated to a much greater extent. The main reason 
for this is the slower kinetics of drying of the larger droplets. Due to this some of the 
drug is deposited in the centre whereas the polymer tends to move at the edge 
taking along the remaining drug forming a mixture where in some areas it is not 
homogenous according to the AFM results .. The justification of the spot formation 
like in the samples represented in chapter 3 can be based on the different solubility 
of the compounds has in the solvents. More specifically in the mixtures of HCT/PLGA, 
the HCT is soluble in acetone but not in OMSO, and hence it will precipitate before 
the ring is formed, since OM SO will be the last to evaporate inducing the coffee ring 
formation of PLGA. 
The addition of pluronic results to a more uniform product where all the compounds 
are equally distributed. This is maybe due to the interactions between the pluronic 
and PLGA via hydrogen bonding of the ether groups of pluronic with the hydroxyl 
groups of PLGA [20S]. When pluronic is added, the solvent system consists of 
acetone, ethanol and OMSO. Pluronic is not soluble in OMSO [177] and therefore it 
will precipitate together with the HCT, which is slightly soluble In ethanol, without 
forming the coffee ring formation. PLGA will be the last to precipitate where pluronic 
can hold the PLGA molecules closer. 
Finally, Raman studies of the samples produced by pippetting and by inkjet printing 
gave results similar to the product produced by the GeSim dispenser in chapter 3. 
Specifically, Raman studies showed a shift towards lower wavenumbers and a shift of 
the symmetric vibration of SO group of HCT indicating disruption of the hydrogen 
bonding between the SO groups and the amino groups among the HCT molecules 
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and formation of hydrogen bonding between the amino groups of HCT and the 
carbonyl groups of PlGA. A more thorough analysis of the phenomenon is described 
in the chapter 3. where it was observed in the samples produced by the GeSim 
dispenser. Nevertheless, as in that chapter the carbonyl peak of PLGA remain in the 
same position with the unprocessed material. This may happen due to the limited 
number of carbonyl ions which take part in the hydrogen bonding formation and 
hence the peak shift that may occur is covered by the broad and strong peak of the 
inert carbonyl groups. Finally, it is important to mention that a second peak 
appeared next to the carbonyl peak of PLGA in the spectra used to create the 
chemical map of the samples results from noise from the instrument and not a 
carbonyl peak shift as the most detailed Raman spectra in Figure 6.17 showed since 
by using higher acquisition time this figure has been remove. 
In terms of captopril, the Raman studies showed that the printed API is in that cis-
form as the carbonyl peak at 1642cm'l appeared at higher wavenumbers whereas 
the peak of the carbonyl peak at 1700 appeared in lower wavenumbers from the 
powder Captopril. This was also confirmed by the product produced with the GeSim 
dispenser in chapter 3 where a detailed analysis of the phenomenon is represented. 
The last step to investigate any drug formulation is to study the release of the APls 
from it. Both captopril and hydrochlorothiazide are freely soluble in the medium 
used. PlGA was chosen to create a polymer matrix which can control drug release. 
PlGA has been widely used to control the release of freely soluble drugs [206, 217-
219]. The mechanisms involved the release of the drug from polymeric matrixes are 
swelling, diffusion and degradation. However, in our case since the dissolution 
duration lasts for only 2hrs and PlGA (85:15) requires days in order to be degraded; 
hence, the main release mechanism of the APls from the polymer Is likely to be 
diffusion. Also, it is interesting to notice that both in the case of captoprll/PlGA and 
HCT /PLGA when 30/70 Is used the release rate is similar even though it would be 
expected that HCT would be released at a slower rate. More specifically, HCT as a 
base will be protonated in the acidic environment. Moreover, PlGA exhibits free 
carboxylic groups which would demonstrate electrostatic interactions with the 
protonated HCT, inhibiting the diffusion of the API. In contrast, captopril as an acid 
will be deprotonated and exist as negative ions. Hence electrostatic interactions 
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between the API and the polvmer cannot exist. The fact that both the HCT and 
Captopril follow the same dissolution profile indicates that these interactions do not 
affect the diffusion of the drug from the polvmer. Also, the reason why onlv 60% of 
both the APls are released must be due to fact that the polvmer covers the rest of 
the API. The rest of the drug will be dissolved when the polvmer starts being eroded 
where the medium will be inserted into its structure dissolving the drug. The 
prolonged release of the 20/80 HCT/PLGA mixture may be attributed to the 
formation of a more homogenous and intimate mixture with the drug and the 
polvmer. 
In order to achieve a complete release of the API as in the commercial tablets, 
Pluronic- f127 was attempted to incorporate with the.polvmer. From Figure 6.21, it is 
clear that the Pluronic has a significant effect on the release of the API. The addition 
of Pluronic results in a more rapid release of the entire API within 40mins. In terms of 
the mechanism that governs the release, it could be expected a priori that the 
hvdrophilic poloxamer would quicklV leach out from the PLGA leaving pores which 
allow the medium to dissolve the API mixed within the polvmer. 
To investigate the release API from the formulation the zero order, first order, 
Higuchi and Korsmever - Peppas model were applied. The suitability of each model 
to describe the mechanism of the drug release was based on the calculation of the R2 
for the formulations. From the table 6.1 , most of the formulations follow the data 
fitting of the Korsmever - Peppas model. More specificallv, in terms of 
hvdrochlorothiazide mixtures, data fitting for HCT/PLGA 20/80 gives a high ~ ~ value of 
0.99. The n value is equal to 0.55 which indicates a non-Fickian release. The mixture 
of HCT/PLGA 30/70 seems to be closer to the non-Fickian Higuchi model with R2 = 
0.933. The release of the HCT/PLGA SO/SO does not seem to follow any of the 
proposed models as the R2 value is low in all the cases. From the mixtures of 
HCT/PLGA/Pluronic onlv the 30/65/5 was able to correlate with the proposed 
models. This mixture seems to follow the Peppas model with n value equal to 0.216. 
In the case of captopril mixtures, for a better fitting with the proposed models the 
first two time points have been excluded. During this time period the API which is 
phase separated is burst from the formulation. Figure 6.24 shows that the release of 
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captopril follows the Peppas model having R2 value equal to 0.94 in both the cases. 
The n values are equal to 0.35 and 0.116 which indicates a Fickian release model. 
It has been suggested that when the n exponent is less than 0.5 is due to drug 
diffusion partially through a swollen matrix and water filled pores in the formulations 
[220]. This looks to be valid in the formulations presented in this chapter. As It has 
been shown before from the AFM and Raman microscopy the samples are phase 
separated. Hence in these cases, the phase separated drug which is exposed to the 
medium was dissolved first, leaving big pores which due to the small sizes of each 
spot, compared to medium, filled with the solution following a Fickian diffusion. 
Besides the good fitting of some formulations with selected models, no complete 
description could be found in current models. Especially the samples with pluronic 
where the drug is released completely in less that 20mins was not able to fit to any 
of the model. Therefore, the obtaining of more values below 20m ins is necessary to 
correlate the drug release with the models. However, the limitations of the models 
can justify any deviation of the release profile from them. In the Higuchi model, the 
device geometry must be a thin film with negligible edge effects, the size of the drug 
particles should be much smaller than the thickness of the film, the carrier material 
should not swell or dissolve and perfect sink conditions should prevail. In our 
systems most of the aforementioned prerequisites can be fulfilled as the spots can 
be considered thin films to an extent but clearly not completely. 
In terms of the Korsmeyer - Peppas model the release is modelled to occur in a one-
dimensional manner and the system width-thickness or length-thickness relation 
must be at least 10, as well as assumptions about constant diffusivities of a drug with 
a polymer, constant dimensions of a device during an In vitro release test, one-
dimensional diffusional behaviour, and perfect sink conditions in an In vitro release 
test. Finally, these models a better fit is obtained when apparatus I or II are used for 
the dissolution test. In our case the dissolution test was carried out on a shaking 
stage which may affect the final results. 
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zero 1st Higuchi Korsmeyer-
order order Peppas 
HCT/PLGA = 50/50 0.75 0.42 0.88 0.9 
HCT /PLGA = 30/70 0.64 0.48 0.93 0.86 
HCT/PLGA = 20/80 0.87 0.68 0.99 0.99 
HCT/PLGA/Pluronic = 
0.41 0.3 0.75 0.9 
30/65/5 
Her /PLGA/Pluronic = 
0.56 0.3 0.84 0.77 
20/75/5 
Captopril/PLGA = 50/50 0.9 0.39 0.86 0.94 
Captopril/PLGA = 30/70 0.53 0.84 0.79 0.94 
l . Table 6.1. r fittmg of the vanous release models for Captopnl/PLGA and HCT/PLGA mIxtures . 
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for the mixtures HCT/PLGA/pluronic at ratio of 20/80,30/70, 50/50 prepared by pippetting deposition . 
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Figure 6.23 : a) Higuchi, b) Korsmeyer-Peppas c)zero order, d) first order for mechanism of drug release 
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6.9 Conclusions 
In this chapter, a successful extended release formulation was prepared using 
Captopril and Hydrochlorothiazide as APls. Captopril and HCT were printed along 
with PLGA which has been used as polymeric matrix to control the release of the 
APls. AFM and confocal Raman mapping revealed phase separation for both the 
mixtures of Captopril/PLGA and HCT/PLGA. Also PCA was proved a powerful 
technique to reveal the location of pluronic which was not able to be observed using 
algorithms from the NGLabspec. 
It was found that pluronics increase the dissolution rate of the HCT significantly. 
Finally, the mechanism of the release of the drug from the polymeric matrix was 
investigated by applying the four most common mathematical models which can 
better, whereas in the case of Captopril there is a Fickian drug release as the describe 
the drug release from monolithic polymeric matrixes. It was found that in the case of 
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HCT/PlGA = 30/70 the Higuchi release kinetic described the system Korsmeyer -
Peppas showed and HCT/PlGA = 20/80 a non fickian drug release is happening. 
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7. Conclusions - Future work 
This aim of the thesis was to prove inkjet printing can be used to produce drug 
formulation product. In order to confirm this, solid dispersion formulations and 
controlled release drug formulation were attempted to be produced. Hence, in 
chapter 3, APls with excipients were successfully printed and characterized. Single 
droplet and multiple droplets of mixtures of felodipine and PVP, captopril with PLGA 
and hydrochlorothiazide with PVP and PLGA were sprayed onto hydrophobic 
substrates. The characterization of felodipine/PVP and HCT /PVP mixtures showed 
that an intimate mixture of the components. However, when PLGA was used both 
captopril and HCT were phase separated with the polymer. 
In chapter 4, the release of felodipine from a single spot was investigated. By using 
the intensity of the characteristics Raman bands of felodipine and PVP, it was shown, 
that the release of the API is directly dependent on the felodipine's concentration in 
the mixture where when felodipine is in its lowest concentration Is dissolved 
completely. However, more investigation needs to be done regarding the effect of 
the concentration of the solute in the release of the API. It has been found that by 
using less concentrated solutions, the API releases quicker which may be either due 
to the increase of surface area. Also for the same reason, the use of a hydrophilic 
surface must be investigated. 
In chapter 5, a proper therapeutic dosage form offelodipine was attempted. For this 
purpose microarrays of felodipine/PVP mixtures were produced and characterised. 
Although each individual spot gave similar AFM, SThM and Raman results, the drug 
was not be able to be released in blank FASSIF solution. In contrast, the dissolution 
test in the FASSIF solution with enzyme results to an immediate release of the API. 
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In chapter 6, the application of inkjet printing was attempted to get extended by 
producing a therapy composed of two APls; captopril and hydrochlorothiazide. As 
captopril and HCT is freely soluble to the dissolution medium, PlGA was used to 
control the release of the API. When the solution was deposited by pipette, the API 
was released from the formulation in a controlled manner. Yet the deposition of 
solution by the microarray printer results to an immediate release of the API which 
can be due to the total increase of surface area as the spots produced by the 
microarray printer are much smaller. 
Even though, this work showed that inkjet printing is a promising drug formulation 
method, there still lot of room for development in this area. First of all, an 
appropriate substrate to print for the deposition of the solution is fundamental to 
apply. This substrate must be biocompatible which could protect the drug from the 
environment allowing It to release in the desired area. Such substrate can be a tablet 
into which the solution will be ejected. Also the porosity of the substrate is of 
fundamental importance. A porous material would allow the solute to be absorbed 
modifying the release of the API or it would be possible that the solvent would not 
be able to evaporate completely. 
Also apart from using a polymer matrix, another approach which could be apply to 
control the release of the API is to coat it with a polymer which would also could 
protect it to release in undesirable areas, by using two different solutions a 
microarray printer could print the solution containing the API at first and 
subsequently the solutions containing the coating material. 
To summarise all the above, it can be concluded that inkjet printing due to its high 
flexibility to produce drugs with tailored properties can gain the interest of 
pharmaceutical industries. The proper technology exists and it is continuously 
developed to handle solutions difficult to be printed, such as viscous solutions. 
Hewlett Packard (HP) has already patented an inkjet device which could produce 
drug formulation [221]. Moreover, recently, Crospon has licensed a 'smart' drug 
delivery skin patch technology from HP labs that uses inkjet printing technology to 
deliver drugs under the skin [222]. These two facts may be the evidence that the 
commercial availability of a device which produces real tailored medicine is not far 
away. 
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